Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population

Marsia Gustiananda 1,*, Bobby Prabowo Sulistyo 1, David Agustriawan 2 and Sita Andarini 3

Citation: Gustiananda, M.; Sulistyo, B.P.; Agustriawan, D.; Andarini, S. Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population. Vaccines 2021, 9, 1459. https://doi.org/10.3390/vaccines9121459

Abstract: SARS-CoV-2 and its variants caused the COVID-19 pandemic. Vaccines that target conserved regions of SARS-CoV-2 and stimulate protective T-cell responses are important for reducing symptoms and limiting the infection. Seven cytotoxic (CTL) and five helper T-cells (HTL) epitopes from ORF1ab were identified using NetCTLpan and NetMHCIIpan algorithms, respectively. These epitopes were generated from ORF1ab regions that are evolutionary stable as reflected by zero Shannon’s entropy and are presented by 56 human leukocyte antigen (HLA) Class I and 22 HLA Class II, ensuring good coverage for the Indonesian and world population. Having fulfilled other criteria such as immunogenicity, IFNγ inducing ability, and non-homology to human and microbiome peptides, the epitopes were assembled into a vaccine construct (VC) together with β-defensin as adjuvant and appropriate linkers. The VC was shown to have good physicochemical characteristics and capability of inducing CTL as well as HTL responses, which stem from the engagement of the vaccine with toll-like receptor 4 (TLR4) as revealed by docking simulations. The most promiscuous peptide 899WSMATYYLF907 was shown via docking simulation to interact well with HLA-A*24:07, the most predominant allele in Indonesia. The data presented here will contribute to the in vitro study of T-cell epitope mapping and vaccine design in Indonesia.

Keywords: SARS-CoV-2; immunoinformatics; T-cell epitopes; multi-epitope peptide-based vaccine; cytotoxic T-cells; helper T-cells; human leukocyte antigen; HLA-A*24:07

1. Introduction

The COVID-19 disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has become a pandemic with dramatic socioeconomic consequences [1,2]. As of 21 September 2021, around 228 million people have been infected and approximately 4.6 million deaths have been reported worldwide (https://covid19.who.int/ accessed on 22 September 2021) [3]. In Indonesia alone, as of 26 September 2021, there have been around 4.2 million confirmed cases with 141,381 deaths (https://covid19.go.id/petasabaranc accessed on 27 September 2021) [4]. The virus was first identified in Wuhan, China, and based on the sequence similarity, was thought to have originated from BatCov RaTG13 [5]. Like any other viral disease, individuals with COVID-19 might have varied symptoms, such as fever or chills, cough, fatigue, muscle aches, headache, or diarrhea. The severity of the symptoms is quite broad, and based on severity; the NIH has classified COVID-19 into five distinct types, namely, asymptomatic, mild, moderate, severe, and critical illness [6]. Patients with severe respiratory illness or acute respiratory distress
syndrome might require intensive care and intubation, and this frequently may lead to
death. Age and the presence of underlying comorbidities seem to determine the course
and outcome of the diseases [7].

SARS-CoV-2 is a positive single-stranded RNA virus with a genome size of 30 kilobases
(kb) containing 10 open reading frames (ORFs) that encode for structural, non-structural,
and accessory proteins. The largest open reading frame of SARS-CoV-2 is called ORF1ab,
occupying the second third of the genome, and encodes a replicase polyprotein 1ab
(7096 amino acids). Polyprotein 1ab must undergo processing by the virally encoded
proteases known as the chymotrypsin-like protease (3CLpro, NSP5) and the papain-like
protease (PLpro, NSP3). Both proteases are initially part of the Polyprotein 1ab before they
were autocatalytically cleaved from the strand and released. The proteases then cleave
the other proteins from the Polyprotein 1ab into a total of 16 non-structural proteins, which
are involved in replication and transcription of viral genome [8,9]. The rest of the genome
(10 kb) encodes for five structural proteins, namely, nucleocapsid (N), membrane (M),
surface (S), and envelope (E) proteins and accessory proteins, namely, ORF3, ORF6, ORF7,
ORF8, and ORF10 [10].

Vaccines are one of the most important countermeasures against the dire consequences
of SARS-CoV-2 spread in the human population. Current vaccines are quite effective in
controlling mortality, morbidity, and hospitalization related to COVID-19. Many of the
vaccines are aiming to induce the response of antibodies against the spike glycoproteins,
which will lead to blockage of viral entry into the cells. However, the emergence of the new
variants raises concerns about the long-term effectiveness of the vaccines and escape from
antibody detection [11]. SARS-CoV-2 variants emerged due to the high mutation rates of
the RNA viruses pertaining to the low fidelity of the RNA-dependent RNA polymerase
(RdRp). In SARS-CoV-2, high mutation frequency was observed for the S protein. Some of
the variants have caused significantly higher fatality rates in some countries [12]. These
variants have a D614G mutation in the spike proteins which was hypothesized to increase
the infectivity of the SARS-CoV-2 virus [13]. As of 23 September 2021, the Centre for Disease
Control and Prevention (CDC) has designated these virus variants into four categories,
namely, Variant Being Monitored (VBM), which includes Alpha (B.1.1.7, Q.1-Q.8), Beta
(B.1.351, B.1.351.2, B.1.351.3), Gamma (P.1, P.1.1, P.1.2), Epsilon (B.1.427 and B.1.429), Eta
(B.1.525), Iota (B.1.526), Kappa (B.1.617.1, B.1.617.3), Mu (B.1.621, B.1.621.1), and Zeta (P.2);
Variant of Concern (VOC) which include Delta (B.1.617.2 and AY.1 sub-lineages); Variant
of Interest (VOI); and Variant of High Consequence (VOHC). At present, no SARS-CoV-2
variants are categorized as VOI and VOHC (https://www.cdc.gov/coronavirus/2019
-ncov/variants/variant-info.html accessed on 24 September 2021) [14].

In a situation where antibodies failed to block viral entry into the cells, the other arm
of adaptive immunity, namely cell-mediated immunity mediated by CTL, is needed to
curb the infection and control the diseases to subclinical level. Inside the infected cells,
viral proteins will undergo HLA Class I pathway, where they will be firstly tagged by
ubiquitin and then digested into short peptides by the proteasome. These short peptides
(8–10 amino acids long) are then translocated with the help of transporter associated with
antigen processing (TAP) into the endoplasmic reticulum (ER) where HLA proteins are
translated. Peptide binds to the HLA molecule and complex is presented on the surface
of the infected cell to be scrutinized by T-cells. Upon recognizing the complex, T-cells kill
the infected cells. The peptides, termed T-cell epitopes, are 8–10 amino acids long and can
originate from any viral proteins, not only the spike glycoprotein. Because T-cell recognizes
an antigen as a complex with HLA molecules, T-cell immunity, therefore, depends on the
HLA molecules that an individual has. In humans, HLA proteins are encoded by the HLA
gene, which is considered the most variable gene within the human genome. In light of the
situation where we expect that the new SARS-CoV-2 variants might occur, identification of
T-cell epitopes that originate from conserved regions of the virus, and utilizing them for
vaccines, should be a priority.
A peptide-based vaccine that induces cell-mediated immunity is a likely choice for emerging virus vaccines, including vaccines for SARS-CoV-2. Viral spike protein is more likely to mutate, and vaccines against it might not be able to prevent the infection. In that situation, having a good T-cell memory that can identify and eliminate infected cells will be beneficial and could potentially save lives. There have been several peptide-based vaccines for COVID-19 in the pipeline undergoing pre-clinical and clinical trials (https://www.who.int/publications/m/item/draft-landscape-of-COVID-19-candidate-vaccines accessed on 25 September 2021) [15]. Several peptides-based vaccines are composed of epitope peptide pool from the spike receptor binding domain (NCT04545749, NCT04683224), spike, and nucleoprotein (NCT04780035), and all proteins of SARS-CoV-2 (NCT04954469, NCT04885361).

ORF1ab, being the largest ORF in the SARS-CoV-2 genome could become the main source of T-cell epitopes. ORF1ab is the first protein to be translated by the infected cell making ORF1ab a good source of early T-cell responses. ORF1ab is also quite stable genetically, with only a small number of mutations in the protein sequences detected when compared to the ancestral sequence of Wuhan Hu-1 [16]. Therefore, in this study, we focused on the identification of conserved and promiscuous CTL and HTL epitopes from ORF1ab to design a multi-epitope peptide-based vaccine that will cover a large portion of human population and be effective against any SARS-CoV-2 variants.

2. Materials and Methods

The overall methodology and protocol for the identification of CTL and HTL epitopes from SARS-CoV-2 ORF1ab is illustrated in Figure 1.

Figure 1. Flowchart indicating the immunoinformatics methods used in this study to identify the CTL and HTL epitopes from SARS-CoV-2 ORF1ab polyprotein.
2.1. SARS-CoV-2 ORF1ab Sequence Retrieval

ORF1ab protein sequence of SARS-CoV-2 Wuhan Hu-1 was retrieved from the reference sequence in NCBI (YP_009724389.1). The reference sequence was used in the prediction of T-cell epitopes. The other SARS-CoV-2 ORF1ab sequences were retrieved from NCBI Virus SARS-CoV-2 Data Hub (https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/SARS-CoV-2) accessed on 22 September 2021. All sequences were retrieved in FASTA format and used for the epitope conservancy analysis. ORF1ab sequences were selected using predefined filters: sequence length 7093–7096 amino acids, the maximum number of ambiguous characters set to 0, human for the host, Pango lineages chosen were Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), Eta (B.1.525), Gamma (P.1), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.7), and Mu (B.1.621), and the completeness option for sequences was set to complete. Due to the large number of delta sequences available in the database, only the isolates from 31 July to 22 September 2021 were included.

2.2. Entropy Analysis of 9-Mer Peptide Sequences

To assess the degree of conservation and variability of 9-mer sequences representing T-cell epitopes within ORF1ab, we calculated Shannon’s entropy according to the methods described in Khan et al. (2017) [17]. Following retrieval of SARS-CoV-2 ORF1ab protein sequences, duplicates were removed using AliView [18] to avoid bias in the calculation of entropy. We then conducted multiple sequence alignment of the remaining sequences using MAFFT v.7.144 (10.1093/molbev/mst010) available on CIPRES portal (https://www.phylo.org/ accessed on 28 October 2021) [19], with default alignment setting. The finished alignment was used as input for entropy analysis using AVANA [20], with sample size set to 9 for 9-mers, entropy values extrapolated to infinite sets with 100 random subalignment sampling to correct for size bias, and highly gapped positions were defined as positions where gaps are 50% of the symbols. The statistics for variability were then imported and processed in Microsoft excel, where the entropy values were plotted against the 9-mer center positions.

2.3. Retrieval of HLA Alleles Type in INDONESIAN Population as the Bases for Prediction

The HLA allele types of Indonesian population were retrieved from The Allele Frequency Net Database (AFND) (http://www.allelefrequencies.net accessed on 21 September 2021) [21]. Most of the HLA alleles data for the Indonesian population listed in AFND came from one study conducted in the Javanese and Sundanese Javanese populations [22]. The data can be considered representative of the Indonesian population, as among 300 distinct ethnic and linguistic groups that exist in Indonesia, Javanese, and Sundanese Javanese are the largest ethnic population, accounting for 40% and 15.5%, respectively (world population review, accessed on 1 October 2021) (https://worldpopulationreview.com/countries/indonesia-population, accessed on 21 September 2021) [23].

2.4. Retrieval of the Number of Experimentally Validated ORF1ab Epitopes Associated with Predominant Indonesian HLA Alleles

Cell-mediated immunity to SARS-CoV-2 has been a topic of interest for many researchers in the last 18 months since the pandemic arose, and hence several identified T-cell epitopes are already available in the Immune Epitope Database (IEDB) [24]. For each HLA allele (with allele frequency > 5%) that the Indonesian population has, we retrieved the information about how many positive T-cell epitopes associated with the alleles are already reported in IEDB (IEDB accessed on 18 September 2021) either by T-cell assay or HLA assay. We then further noted whether the HLA allele is specific to Indonesia or shared with Germany, as representative of the Caucasian population and Thailand as representative of other Southeast Asia population. The HLA alleles for Germany were retrieved from the SARS-CoV-2 T-cell epitopes identification study [25] and HLA alleles of the Thai population were retrieved from a large-scale HLA typing study [26–28] focusing only the HLA alleles with a minimum 5% frequency in the Thai population.
2.5. Prediction of CTL Epitopes from ORF1ab

The 9-mer peptides from ORF1ab were analyzed for their capacity to enter the HLA Class I presentation pathway and become T-cell epitopes that will be recognized by CTL. Immunoinformatics server NetCTLpan 1.1 was used in the analysis (https://services.healthtech.dtu.dk/service.php?NetCTLpan-1.1, accessed on 21 September 2021) [29]. The server calculated all steps involved in the HLA Class I antigen processing and presentation pathways, such as the efficiency of proteasomal cleavage, efficiency of the transporter associated with antigen processing (TAP) to translocate peptides from the cytosol into the endoplasmic reticulum (ER) lumen, and finally predict the binding affinity of peptide to HLA molecules. The parameters for the weight placed on C-terminal cleavage and the antigen transport efficiency were set to the default values of 0.225 and 0.025, respectively. Stringent selection criteria were applied, where only the top 1% rank peptides were considered as CD8⁺ T-cell epitopes and subjected to further analysis. The percentile rank is proportionally related to the binding affinity of the peptide to the HLA molecule. Therefore, the low percentile rank applied here will ensure that only peptides with a higher likelihood to become the real CTL epitopes will be selected. NetCTLpan is the sole prediction server used, as it was developed based on the NetMHCpan method, which was shown to be the best predictor for peptide–HLA binding [30], and it can predict peptide binding to HLA molecules even though the experimental data are not available.

2.6. Prediction of HTL Epitopes from ORF1ab

Immunoinformatics server NetMHCIIpan 4.0 (https://services.healthtech.dtu.dk/service.php?NetMHCIIpan-4.0, accessed on 21 September 2021) [31] was used to predict the binding affinity of the 15-mer peptides to HLA Class II alleles. HLA class II molecules, due to the open conformation of the peptide-binding groove, can accommodate longer peptides, with additional 3 residues on each flank. The binding core of the interaction, however, consists of the 9-mer peptide. Both 15-mer and 9-mer binding core were curated. In this analysis, strong and weak binding is defined by the percentile rank thresholds of 1% and 5%, respectively. The peptides that belong to the strong binders were selected and subjected to further analysis.

2.7. Immunogenicity Analysis of Predicted CTL Epitopes

Binding affinity of peptide to HLA molecule does not determine immunogenicity. Immunogenicity of peptides is determined by the presence of T-cells having T-cell receptor recognizing the peptide-HLA complex [32]. CD8⁺ T-cells recognize peptide antigens as a complex with HLA Class I molecules. Some residues of the peptides (positions 1, 2, and 9) bind to the peptide-binding groove of HLA molecules, and some other residues (positions 3–8) bind to the T-cell receptor. Immunogenicity analysis was conducted using the IEDB immunogenicity tool (http://tools.iedb.org/immunogenicity/, accessed on 21 September 2021) [33]. The higher the score generated by the tool, the more immunogenic the peptide is. In general, the presence of large and aromatic residues is associated with immunogenicity, and residues number 4–6 of the presented peptides was shown to have a large effect on immunogenicity [33]. In this study, all CTL epitopes from ORF1ab peptides chosen in the preceding step were subjected to immunogenicity analysis applying the parameters where residue no. 1, 2, and C-terminal were masked. The peptides with positive immunogenicity scores were selected for further analysis.

2.8. Interferon-Gamma (IFNγ)-Inducing Ability of Predicted HTL Epitopes

The HTL is important for the generation of the cytokines that drive appropriate immune responses. For intracellular pathogens such as viruses, IFNγ is a very important cytokine for CD8⁺ T-cell differentiation into a full effector CTL and memory CTL. HTL come in different subsets, and the subsets that will produce IFNγ were named Th1. Therefore, the ability of HTL epitopes to induce the production of IFNγ was analyzed using the IFNepitope server (http://crdd.osdd.net/raghava/ifnepitope/scan.php, accessed on
21 September 2021) [34]. The parameter for prediction was set as default using the support- 

2.9. Conservancy Analysis of the Predicted Epitopes against SARS-CoV-2 Variants

Both selected CTL and HTL epitopes were subjected to conservancy analysis using 

2.10. Validation of Predicted Epitopes in IEDB Epitopes List

IES DB contains the experimentally known epitopes from the ORF1ab SARS-CoV-2 

Table 1. The number of ORF1ab from SARS-CoV-2 variants included in the study. The sequences 

2.11. Cross-Reactivity of Predicted Epitopes with Human Peptides

The viral peptides having sequences that match with the sequence of the human 

Table 1. The number of ORF1ab from SARS-CoV-2 variants included in the study. The sequences 

SARS-CoV-2 Variants | Number of Isolates |
--- | --- |
Alpha (B.1.1.7) | 158 |
Beta (B.1.351) | 374 |
Delta (B.1.617.2) | 1157 |
Eta (B.1.525) | 436 |
Gamma (P.1) | 9 |
Iota (B.1.526) | 24 |
Kappa (B.1.617.1) | 148 |
Lambda (C.7) | 286 |
Mu (B.1.621) | 18 |

The viral peptides having sequences that match with the sequence of the human self-peptides might induce either autoreactive T-cells or tolerogenic T-cells. The first one will cause an autoimmune response while the latter will reduce the immunogenic- 

The Bl ast P analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed on 21 September 2021) was conducted to find 9-mer peptide sequences within the human (taxid: 9606) proteome that match with the 9-mer sequences derived from SARS-CoV2, since both HLA Class I and Class II have peptide-binding core regions that can accommodate peptides with a 9 amino acid length. The BlastP algorithm parameter was set as follows: expect threshold 30,000, word size 2, matrix PAM30, gap cost was set to 

The results from BlastP analysis were transferred into Microsoft Excel and were screened for the peptides that shared at least contiguously 7 identical amino acid residues with the human peptides with no gap and no mismatches residue.
2.12. Epitope Selection and Vaccine Construction

Selection of the epitopes to be included in the VC followed several criteria: (1) Epitopes should be promiscuous so that they can be presented by many HLA alleles and hence generate a high-population coverage of the vaccine. (2) Epitopes presented by HLA Class I should be immunogenic so that there will be T-cells within the repertoire that will be able to respond to the peptides. (3) Epitope presented by HLA Class II should be able to induce IFN-γ responses so that vaccine will be able to activate the Th1 responses that are needed for antiviral immune responses. (4) Epitopes should not have homology with the human peptides so that autoimmune responses triggered by the vaccine can be avoided while ensuring the immunogenicity of the VC.

The vaccine was designed by joining individual epitopes into a polypeptide. β-defensin was used as an adjuvant and will serve as a ligand for the TLR4 that is needed for dendritic cell maturation and successful T-cell activation in the lymph node. β-defensin, HTL, and CTL epitopes were connected using linkers EAAAK, GPGPG, and AAG, respectively [36].

2.13. Evaluation of VC Properties: Antigenicity, Allergenicity, Toxicity, and Physicochemical Characteristics

Antigenicity prediction was conducted using Vaxijen (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html, accessed on 21 September 2021) [37] with the chosen parameter as follows: virus as target organism and score 0.4 as the antigenicity threshold.

Allergenicity analysis of the VC was conducted using two servers, namely Allertop 1.0 (http://www.pharmfac.net/allertop/, accessed on 21 September 2021) [38] and AllergenFP v.1.0 (https://ddg-pharmfac.net/AllergenFP/index.html, accessed on 21 September 2021) [39]. Allertop 1.0 method was trained using a set of equal number of known allergens (2210) and non-allergens (2210) from the match species. AllergenFP v.1.0 was trained using a set of 2427 allergens and 2427 non-allergens which are assembled into a matrix for prediction.

Physicochemical characteristics of the VC such as amino acid composition, molecular weight, pI, half-life, stability, and grand average of hydropathicity (GRAVY) were evaluated using Protparam tools (https://web.expasy.org/cgi-bin/protparam/protparam, accessed on 21 September 2021). The tools deduced these properties from a protein sequence [40]. These properties need to be considered for successful manufacturing process of the VC.

The possibility that the VC will generate toxic peptides was evaluated using Toxin-pred (https://webs.iiti.d.edu.in/raghava/toxinpred/index.html, accessed on 21 September 2021) [41]. The module Protein Scanning was used to generate all possible overlapping 10-mer peptides and predict the toxicity of the peptides using the SVM (Swiss-Prot)-based method with the threshold set to 0.0.

2.14. Re-Analyze the VC for Epitopes Generation and Homology with Human Proteins and Human Microbiome

The VC was analyzed to recheck that the CTL and HTL epitopes, which were put into the construct, will be generated, and that the other 9-mer peptides that might be generated do not have homology with human peptides and human microbiomes. CTL and HTL epitopes prediction were conducted using NetCTLpan1.1 and NetMHCIIpan4.0, respectively. BlastP was used to check for the peptide homology with human peptides.

The similarity of T-cell epitopes with the human microbiome might either dampen or increase immunogenicity [42]; therefore, it is important to validate that the vaccine will not disrupt immune homeostasis in the gut. A possibility that vaccine construct might generate epitopes that are homologous to the epitopes from the human microbiome was checked using Pipeline Builder for Identification of drug Targets (PBIT) server (http://www.pbit.bicnirrh.res.in/index.php, accessed on 21 September 2021) [43]. Predicted peptides were submitted as FASTA files to the PBIT server to check for sequence
identity with the peptide from human microbiome. The peptides would be considered as non-homologous if the sequence identity was <50% and e-value was >0.005.

2.15. Immune Simulation of the VC

Immunological responses generated by the VC were assessed in silico using C-ImmSim online server (https://kraken.iac.rm.cnr.it/C-IMMSIM/, accessed on 21 September 2021) [44]. The simulation was conducted for the highest frequency of HLA haplotype found in the Indonesian population namely haplotype HLA-A*3401, HLA-B*1521, HLA-DRB1*1502 (4.6%), and HLA-A*2407, HLA-B*3505, HLA-DRB1*1202 (4.3%) [22]. In order to simulate prime-boost-boost vaccination, the simulation was run for a total of 1000 phases with three injections of 1000 units of vaccine that were given at an interval of four weeks apart (day 0, 28, and 56) that correlated with 1, 84, and 168 time-steps parameters in the simulation server. Note that 1 time-step is equal to 8 h and the injections were administered four weeks apart [45].

2.16. Population Coverage of the VC

The population coverage of the VC was evaluated using the population coverage analysis tool housed in IEDB (http://tools.iedb.org/population/, accessed on 21 September 2021) [35]. The population coverage analysis was conducted to ensure that the T-cell epitope-based vaccine will cover a large population. T-cell recognizes peptides presented by HLA molecules, and different ethnicities will express HLA types at different frequencies. The predicted population coverage represents the percentage of individuals that will respond to the VC and generate an immune response.

2.17. Secondary Structure and Tertiary Structure Prediction of the VC

The secondary structure of the VC was predicted using SOPMA (https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_sopma.html, accessed on 21 September 2021) [46], which is one of the automated methods of protein secondary structure prediction from multiply aligned protein sequences. RAPTOR X was used to validate the secondary structure and predict the tertiary structure of the VC (http://raptorx.uchicago.edu/ContactMap/, accessed on 21 September 2021) [47,48]. RAPTOR X predicts the tertiary structure based on the inter-residue distance distribution of a protein by the deep learning method. The server works best for predicting protein structures that do not have many sequences homology, and it has proven to be the best server for contact prediction that can be run using a personal computer [49]. Tertiary structure generated by RAPTOR X was then validated by using ProSA-web (https://prosa.services.came.sbg.ac.at/prosa.php, accessed on 21 September 2021) [50]. The PDB structure generated by RAPTOR X was used as an input file for ProSA-web, which will compare the predicted 3D model of the VC with the existing proteins structure in PDB database that were generated experimentally either by X-ray crystallography or NMR. ProSA-web then calculated the z-score, which represents the quality index of the model. Graphically, the z-score value is displayed in a plot that contains the z-scores of all experimentally determined protein chains in the PDB database, where dark blue and light blue area represents NMR and x-ray structures, respectively. The z-score value of the predicted model is displayed as a black dot in the graph, and the model quality is acceptable if it falls within the range of scores typically found for native proteins of similar size.

2.18. Molecular Docking of the VC with TLR4

The interaction between the vaccine and TLR4 (PDB ID: 3FXI) was modeled using HDOCK (http://hdock.phys.hust.edu.cn/, accessed on 21 September 2021) [51,52]. HDOCK generates information about the interacting residues between TLR4 and the vaccine. The PDB file of TLR4 (3FXI) and PDB file of the VC that was generated by RAPTOR X was used as input files for prediction. The complex interaction was also analyzed using
ClusPro protein–protein docking server (https://cluspro.bu.edu/home.php, accessed on 21 September 2021) [53]. Similar to HDOCK, the PDB of the receptor was 3FXI, and the PDB file of the VC that was generated by RAPTOR X was used as the ligand. The model with the lowest binding energy was chosen and the interacting residues were visualized using PDBsum (http://www.ebi.ac.uk/thornton-srv/databases/pdbsum/Generate.html, accessed on 21 September 2021) [54]. The PROCHECK tool that was integrated into PDBsum calculated the number of residues in the favored region as an indication of a good model.

2.19. Molecular Docking of Peptide WSMATYYLF with HLA-A*24:02 and HLA-A*24:07

As a means to validate the T-cell epitope prediction, we docked the peptide to the HLA molecules and analyzed the interaction. There were two steps to perform the analysis. The first step involved determination of HLA structure and generation of the PDB file. PDB structure of HLA-A*24:02 and HLA-A*24:07 were inferred from their residues. The different between HLA-A*24:02 and HLA-A*24:07 was only one residue number 70 in HLA-A*24:02 is histidine, and in HLA-A*24:07 is glutamine. The protein sequences were submitted to I-TASSER server (https://zhanggroup.org/I-TASSER/, accessed on 21 September 2021) to predict the structure. The PDB file of the best protein structure model of HLA-A*24:02 and HLA-A*24:07 was then downloaded from I-Tasser online server after the computation was finished. The best PDB model was defined as the one having the highest C-score. The pdb data were used as the input for the molecular docking analysis. The second step was the molecular docking of peptide WSMATYYLF to the HLA molecule, which was computed through CABS-dock web server (http://biocomp.chem.uw.edu.pl/CABSdock accessed on 26 October 2021) [55–57]. The analysis was run with the default CABS-dock mode and the model of the protein–peptide complex with the highest score was considered.

3. Results

3.1. SARS-CoV-2 ORF1ab Polyprotein Contains Evolutionary Stable Regions with Low Entropy

One important factor that needs to be considered in the vaccine formulation is the conservancy of the epitopes. Therefore, the sequences of ORF1ab from the SARS-CoV-2 Wuhan Hu-1 isolate (NCBI Reference Sequence YP_009724389.1) and its variants including the VOC and VOI were obtained (Table 1) and checked for sequences conservancy. As T-cells receptors recognize antigen in the form of 9-mer peptide presented by HLA molecule, we checked for the conservancy of the 9-mers using the AVANA tool. The AVANA tool generates Shannon’s entropy, which is a parameter to infer evolutionary stabilities of any given 9-mer sequences within a complete protein. Low entropy values (zero or close to zero) suggest highly conserved positions. The AVANA results showed that the entropy values of SARS-CoV-2 ORF1ab 9-mers range from 0.00 to 1.44. As displayed in Figure 2, the vast majority of 9-mer sequences from ORF1ab were of very low entropy, which suggests that the protein has low variability, high conservancy, and evolutionarily stable. Theoretically, the highest possible 9-mer entropy value is 39 [17]; however, the values are much lower when comparing closely related viral variants. For instance, a similar entropy analysis of SARS-CoV-2 spike protein yielded high occurrence of positions with high entropy (>0.800), identified as mutation hotspots [58].

3.2. SARS-CoV-2 ORF1ab Contributes a Large Number of Experimentally Known Immunogenic Epitopes in IEDB

IEDB contains the information about T-cell epitopes that were proven experimentally to be recognized by T-cells in assays such as IFNy ELISPOT and intracellular cytokine staining flow cytometry. The presence of T-cells recognizing the epitopes indicates that the epitopes are immunogenic. Applying the assumption that the epitopes are mostly 9-mers, the percentage of immunogenic epitopes over the possible number of epitopes generated per protein was calculated (Table 2).
displayed in Figure 2, the vast majority of 9-mer sequences from ORF1ab were of very low
entropy, which suggests that the protein has low variability, high conservancy, and evo-
lutionarily stable. Theoretically, the highest possible 9-mer entropy value is 39 [17]; how-
ever, the values are much lower when comparing closely related viral variants. For in-
stance, a similar entropy analysis of SARS-CoV-2 spike protein yielded high occurrence
of positions with high entropy (>0.800), identified as mutation hotspots [58].

Figure 2. Entropy values of SARS-CoV-2 ORF1ab protein 9-mers. Blue line denotes the entropy values for 9-mer in the
corresponding center position. Yellow vertical lines in the background depicts the occurrence of 0 entropy.

Table 2. The number of SARS-CoV-2 immunogenic epitopes (T-cell assay positive) as reported in IEDB. The percentage of
immunogenic epitopes over the possible number of 9-mer peptides generated by a protein was calculated. The number
in bold indicates the percentage of the immunogenic epitopes over the total number of epitopes. IEDB is accessed on
16 September 2021.

| Protein   | Size (aa) | Number of Immunogenic Epitopes Reported in IEDB (T-Cell Assay Positive) | % Immunogenic Epitopes Per Protein | % Immunogenic Epitopes Per Total Reported in IEDB |
|-----------|-----------|------------------------------------------------------------------------|-----------------------------------|-----------------------------------------------|
| ORF1ab    | 7096      | 678                                                                    | 9.6                               | 38.4                                          |
| Spike     | 1273      | 578                                                                    | 4.5                               | 32.7                                          |
| ORF3a     | 275       | 88                                                                     | 32.0                              | 5                                             |
| Envelope  | 75        | 13                                                                     | 17.3                              | 0.7                                           |
| Membrane  | 222       | 131                                                                    | 59.0                              | 7.4                                           |
| ORF6      | 61        | 18                                                                     | 29.5                              | 1.0                                           |
| ORF7a     | 121       | 28                                                                     | 23.1                              | 1.6                                           |
| ORF7b     | 43        | 3                                                                      | 7.0                               | 0.2                                           |
| ORF8      | 121       | 37                                                                     | 30.6                              | 2.1                                           |
| Nucleocapsid | 419     | 185                                                                    | 44.2                              | 0.5                                           |
| ORF10     | 38        | 8                                                                      | 21.0                              | 0.5                                           |
| Total epitopes |       | 1767                                                                  |                                    |                                                |

Although only 10% of the possible ORF1ab T-cell epitopes were reported to be im-
munogenic, ORF1ab contributed significantly (38.5%) to the total number of SARS-CoV-2
T-cell epitopes reported in IEDB. Table 2 shows all proteins of SARS-CoV-2 could poten-
tially be the source of immunogenic T-cell epitopes, as these epitopes were experimentally
proven by T-cell assay. A large proportion of epitopes per protein are generated from
the spike, membrane, and nucleocapsid protein, with the percentages of 45.4, 59.0, and
44.2%, respectively. Despite only 9.6% of the ORF1ab polyprotein being T-cell epitopes, the
number of these immunogenic epitopes contributes 38.4% of the total reported epitopes
due to the large size of the protein. A large number of potential epitopes would allow more
flexibility in finding peptides that are immunogenic and conserved among SARS-CoV-2
variants. Therefore, peptides from SARS-CoV-2 ORF1ab polyprotein would be useful in
the pan-universal SARS-CoV-2 vaccines development.

3.3. HLA Allele Frequencies of the Indonesian, Thai, and German Population

In order to see the diversity of HLA alleles in different populations, the HLA alleles of
the Indonesian, Thai, and German population and their frequencies were plotted in
Figure 3. The most predominant HLA Class I alleles in Indonesian population were HLA-A*24:07 (20.7%), HLA-A*33:03 (16.9%), HLA-A*11:01 (16.4%), HLA-A*24:02 (14.4%), HLA-
B*15:13 (11.0%), and HLA-B*15:02 (10.7%), while the most predominant HLA Class II alleles were HLA-DRB1*12:02 (36.8%), HLA-DRB1*15:02 (24.1%), and HLA-DRB1*07:01 (13.7%). Comparing the allele frequency of Indonesia with Thailand and Germany (Figure 3) clearly shows that allele frequency is characteristic for each population. While HLA-A*24:07 had the highest frequency in the Indonesian population (21%), it is much lower in Thailand (5%), and almost none in Germany (0.03%). On the other hand, HLA-A*02:01 was predominant in Germany (27%), but much lower in both Indonesia (7.5%) and Thailand (1.8%). The differences in the allele frequency between populations need to be considered to avoid bias in the formulation of T-cell epitope-based vaccine.

**Figure 3.** Indonesian HLA alleles and frequency. There were 56 HLA Class I and 22 HLA Class II alleles included in the study. The allele frequency in the Indonesian population (red bar) was compared to those in Thailand (Green bar) and Germany (Blue bar).
3.4. Asian HLA Alleles Are Less Studied as Compared to the HLA Alleles Predominant in the European Population

Table 3 shows the number of SARS-CoV-2 T-cell epitopes that are associated with HLA alleles of the Indonesian, Thai, and German populations. Comparing the number of reported T-cell epitopes presented by HLA alleles revealed that there was no information about epitopes associated with some of the HLA alleles significant for the Asian population such as HLA-A*24:07, A*33:03, and B*15:13. This indicates that these HLA alleles are less studied as compared to the HLA alleles predominant in the European population and stresses the need for more T-cell assays conducted using samples from convalescent individuals from Indonesia and Thailand.

Table 3. The number of experimentally known T-cell epitopes associated with HLA alleles of Indonesia (INA), Thailand (THA), and Germany (GER). The HLA alleles listed are predominant in the Indonesian and Thai populations (allele frequency ≥ 5%). The HLA alleles of the German population are the ones included in a study of T-cell responses to SARS-CoV-2 [25]. The number of immunogenic T-cell epitopes associated with the alleles were extracted from IEDB (accessed on 16 September 2021).

| HLA Alleles | Populations | ORF1ab T-Cell Epitopes | SARS-CoV-2 T-Cell Epitopes | % ORF1ab/SARS-CoV-2 Epitopes in T-Cell Assay |
|-------------|-------------|------------------------|---------------------------|---------------------------------------------|
|             |             | Total                  | T-Cell Assay              | HLA Assay                                  | Total                  | T-Cell Assay | HLA Assay | % ORF1ab/SARS-CoV-2 Epitopes in T-Cell Assay |
| A*01:01     | GER         | 54                     | 48                        | 12                                         | 96                     | 85           | 21        | 56.47                                        |
| A*02:01     | GER, INA    | 138                    | 82                        | 86                                         | 224                    | 156          | 126       | 52.56                                        |
| A*02:03     | INA, THA    | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| A*02:07     | THA         | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| A*03:01     | GER         | 42                     | 17                        | 33                                         | 69                     | 37           | 45        | 45.95                                        |
| A*11:01     | GER, INA, THA | 49          | 19                        | 39                                         | 69                     | 33           | 48        | 57.58                                        |
| A*24:02     | GER, INA, THA | 64          | 45                        | 29                                         | 129                    | 100          | 47        | 45.00                                        |
| A*24:07     | INA, THA    | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| A*33:03     | INA, THA    | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| A*34:01     | INA         | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| B*07:02     | GER         | 38                     | 34                        | 4                                          | 81                     | 72           | 13        | 47.22                                        |
| B*08:01     | GER         | 26                     | 25                        | 1                                          | 56                     | 52           | 4         | 48.08                                        |
| B*13:01     | THA         | 0                      | 0                         | 0                                          | 1                      | 1            | 0         | 0.00                                         |
| B*15:01     | GER         | 34                     | 29                        | 5                                          | 56                     | 44           | 12        | 65.91                                        |
| B*15:02     | INA, THA    | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| B*15:13     | INA         | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| B*15:21     | INA         | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| B*18:01     | INA, THA    | 1                      | 0                         | 1                                          | 3                      | 0            | 3         | 3                                             |
| B*35:05     | INA, n.a.   | n.a.                   | n.a.                      | n.a.                                       | n.a.                   | n.a.         | n.a.     | n.a.                                         |
| B*38:02     | INA         | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| B*40:01     | GER, THA    | 41                     | 18                        | 28                                         | 67                     | 33           | 41        | 54.55                                        |
| B*44:03     | INA, THA    | 11                     | 11                        | 0                                          | 25                     | 25           | 0         | 44.00                                        |
| B*46:01     | THA         | 0                      | 0                         | 0                                          | 0                      | 0            | 0         | 0                                             |
| B*58:01     | INA, THA    | 6                      | 0                         | 6                                          | 14                     | 0            | 14       | 14                                           |
| DRB1*01:01  | GER         | 8                      | 4                         | 7                                          | 61                     | 8            | 59        | 50.00                                        |
| DRB1*03:01  | GER, THA    | 1                      | 0                         | 1                                          | 28                     | 20           | 15        | 0.00                                         |
| DRB1*04:01  | GER         | 24                     | 2                         | 24                                         | 156                    | 5            | 156      | 40.00                                        |
### Table 3. Cont.

| HLA Alleles | Populations | ORF1ab T-Cell Epitopes | SARS-CoV-2 T-Cell Epitopes | % ORF1ab/SARS-CoV-2 Epitopes in T-Cell Assay |
|-------------|-------------|------------------------|---------------------------|---------------------------------------------|
|             |             | Total                  | T-Cell Assay             | HLA Assay | Total | T-Cell Assay | HLA Assay |                          |
| DRB1*04:05  | THA         | 1                      | 0                         | 1         | 39    | 0             | 39       |                          |
| DRB1*07:01  | GER INA     | 9                      | 9                         | 1         | 63    | 34            | 40       | 26.47                      |
| DRB1*09:01  | THA         | 1                      | 0                         | 1         | 38    | 0             | 38       |                          |
| DRB1*11:01  | GER INA     | 1                      | 0                         | 1         | 42    | 12            | 32       | 0.00                       |
| DRB1*12:02  | INA THA     | 0                      | 0                         | 0         | 3     | 3             | 0        | 0.00                       |
| DRB1*14:54  | THA         | 0                      | 0                         | 0         | 0     | 0             | 0        |                          |
| DRB1*15:01  | GER INA     | 17                     | 14                        | 7         | 83    | 50            | 58       | 28.00                      |
| DRB1*15:02  | INA THA     | 2                      | 2                         | 0         | 10    | 10            | 0        | 20.00                      |
| DRB1*16:02  | INA THA     | 0                      | 0                         | 0         | 8     | 8             | 0        | 0.00                       |

3.5. Prediction of CTL Epitopes and Evaluation of Immunogenicity

CTL epitopes from ORF1ab were predicted using NetCTLpan 1.1 against a panel of 56 HLA Class I alleles as shown in Figure 2. NetCTLpan 1.1 analysis generated, in total, 1132 9-mer peptides with the percentile rank less than 1% for the HLA Class I allele. The number of peptides that bind per HLA allele is shown in Figure 4. HLA-A*29:01 (allele frequency of 0.008) binds to the highest number of peptides (126), while HLA-B*13:01 (allele frequency of 0.015) binds the lowest number of peptides (19). The top five most predominant HLA Class I alleles in the Indonesian population HLA-A*24:07 (allele frequency of 0.207), HLA-A*33:03 (0.169), HLA-A*11:01 (0.164), HLA-A*24:02 (0.144), and HLA-B*15:13 (0.11) bind 83, 72, 111, 82, and 71 peptides, respectively. Up to this stage, we were able to identify in silico the peptides that could potentially bind to the understudied HLA alleles (no data in IEDB, as shown in Table 3) such as HLA-A*24:07, A*33:03, and B*15:13.

![Figure 4](image_url)

**Figure 4.** The number of predicted CTL epitopes that are presented by the HLA Class I allele. NetCTLpan 1.1 predicted 1132 9-mer peptides that bind to at least 1 HLA Class I alleles with the percentile rank of less than 1%.
A total of 1132 peptides were shortlisted further. Peptides bound to only one allele of HLA Class I were removed from the list since they were not preferable due to the possibility of having low population coverage if these peptides were used in a VC. The selected peptides were then evaluated using the IEDB Immunogenicity analysis tool and revealed that 410 peptides were shown to have a positive immunogenicity score. The 9-mer peptides were further screened for the possibility to bind to at least one HLA Class II allele, because binding to both Class I and Class II could be beneficial to invoke more robust immune responses. In the end, only 65 peptides fulfilled the criteria (Table 4) and were therefore selected for further evaluation.

Table 4. List of 9-mer peptides from ORF1ab predicted as promiscuous CTL epitopes.

| Start Residue | Peptide | HLA Class I Alleles | Immunogenicity Score |
|---------------|---------|---------------------|----------------------|
| 295           | FMGRIRSVY | HLA-A*01:01, HLA-A*29:01, HLA-B*15:01, HLA-B*15:02, HLA-B*15:12, HLA-B*15:13, HLA-B*15:21, HLA-B*15:25, HLA-B*15:32, HLA-B*35:01, HLA-B*35:05, HLA-B*35:30, HLA-B*46:01 | 0.1259 |
| 541           | RVVRSIFSR | HLA-A*03:01, HLA-A*11:01, HLA-A*11:04, HLA-A*33:03, HLA-A*74:01 | 0.0318 |
| 611           | WLTNIFGTV | HLA-A*02:01, HLA-A*02:03 | 0.2972 |
| 806           | MVTNNNTFTL | HLA-A*02:06, HLA-A*34:01, HLA-B*35:02, HLA-B*35:30, HLA-B*56:01, HLA-B*56:02, HLA-B*46:01 | 0.1578 |
| 899           | WSMATYYLF | HLA-A*01:01, HLA-A*24:02, HLA-A*24:07, HLA-A*24:10, HLA-A*29:01, HLA-A*32:01, HLA-B*13:01, HLA-B*15:02, HLA-B*15:12, HLA-B*15:13, HLA-B*15:17, HLA-B*15:21, HLA-B*15:25, HLA-B*15:32, HLA-B*18:01, HLA-B*18:02, HLA-B*35:01, HLA-B*35:05, HLA-B*35:30, HLA-B*52:01, HLA-B*56:07, HLA-B*57:01, HLA-B*58:01, HLA-B*46:01 | 0.0071 |
| 1055          | VVVNAANVY | HLA-A*26:01, HLA-B*15:01, HLA-B*15:02, HLA-B*15:12, HLA-B*15:21, HLA-B*15:25, HLA-B*35:01, HLA-B*35:05, HLA-B*46:01 | 0.1005 |
| 1140          | HEVLLAPLL | HLA-B*13:01, HLA-B*18:01, HLA-B*18:02, HLA-B*37:01, HLA-B*38:02, HLA-B*40:01, HLA-B*40:02, HLA-B*40:06, HLA-B*41:01, HLA-B*44:03 | 0.0124 |
| 1247          | FLTENLLLY | HLA-A*01:01, HLA-A*26:01, HLA-A*29:01 | 0.0808 |
| 1254          | LYIDINGNL | HLA-A*24:02, HLA-A*24:07, HLA-A*24:10 | 0.2138 |
| 1269          | LVSDIDITF | HLA-B*15:02, HLA-B*15:13, HLA-B*15:17, HLA-B*15:21, HLA-B*35:01, HLA-B*35:02, HLA-B*35:05, HLA-B*35:30, HLA-B*58:01, HLA-B*46:01 | 0.2541 |
| 1366          | ILGTVSWNL | HLA-A*02:01, HLA-A*02:07 | 0.1177 |
| 1674          | YLATALTL | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*02:07, HLA-B*46:01 | 0.0927 |
| 2175          | LLQLCTFTR | HLA-A*33:03, HLA-A*74:01 | 0.0568 |
| 2327          | FLAYILFTR | HLA-A*33:03, HLA-A*74:01 | 0.2496 |
| 2331          | ILFTRFFYY | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*02:07, HLA-A*74:01, HLA-B*08:01, HLA-A*02:07 | 0.3343 |
| 2350          | FSYFAVFI | HLA-B*51:01, HLA-B*51:02, HLA-B*52:01 | 0.2893 |
| 2597          | FSSTFVPM | HLA-B*15:10, HLA-B*15:21, HLA-B*35:01, HLA-B*35:05, HLA-B*35:30, HLA-B*56:02, HLA-B*46:01 | 0.1216 |
| 2629          | LSTFISAAR | HLA-A*33:03, HLA-A*34:01, HLA-A*74:01 | 0.1602 |
| 2784          | AIFYLITPV | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*34:01, HLA-A*02:07 | 0.1750 |
| 2786          | FLYLTPVHV | HLA-A*24:02, HLA-A*24:07, HLA-A*24:10 | 0.2114 |
| 2787          | YLITPVHVM | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*26:01, HLA-B*15:01, HLA-B*15:02, HLA-B*15:10, HLA-B*15:12, HLA-B*15:21, HLA-B*15:25, HLA-B*15:32, HLA-B*35:01, HLA-A*02:07, HLA-B*46:01 | 0.1617 |
| 2883          | FLPRVFSAV | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-B*08:01, HLA-A*02:07 | 0.0821 |
Table 4. Cont.

| Start Residue | Peptide                  | HLA Class I Alleles                      | Immunogenicity Score |
|---------------|--------------------------|------------------------------------------|----------------------|
| 3059          | LAYYFMFRF               | HLA-A*33:03, HLA-A*74:01                 | 0.0559               |
| 3060          | AYYFMFRFR               | HLA-A*33:03, HLA-A*74:01                 | 0.1234               |
| 3076          | VVAFNTILF               | HLA-A*24:07, HLA-A*29:01                 | 0.1449               |
| 3121          | FLHAIQWMV               | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*02:07 | 0.1502               |
| 3137          | FWITIAYII               | HLA-A*24:02, HLA-A*24:07, HLA-A*24:10   | 0.3233               |
| 3152          | FYWFFSNYL               | HLA-A*24:02, HLA-A*24:07, HLA-A*24:10   | 0.1404               |
| 3466          | VLAFLYAAV               | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*02:07 | 0.2772               |
| 3481          | FLNRFITTL               | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-B*08:01, HLA-A*02:07, HLA-B*46:01 | 0.2560               |
| 3582          | LLLTILSL                | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-B*08:01, HLA-A*02:07 | 0.0907               |
| 3605          | LYENAFLPF               | HLA-A*24:02, HLA-A*24:07, HLA-A*24:10   | 0.1584               |
| 3652          | VYMPASWYM               | HLA-A*24:02, HLA-A*24:07, HLA-A*24:10   | 0.0253               |
| 3684          | YASAVVLL                | HLA-A*51:01, HLA-B*51:02, HLA-B*52:01, HLA-B*56:07, HLA-B*58:01 | 0.0489               |
| 3692          | ILMTARTV                 | HLA-A*29:01, HLA-B*15:01, HLA-B*15:02, HLA-B*15:12, HLA-B*15:21, HLA-B*15:25, HLA-B*15:32, HLA-B*35:05, HLA-B*35:30, HLA-B*46:01 | 0.1258               |
| 3752          | FLARGIVF                 | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*02:07 | 0.3263               |
| 4030          | TMLFTMLRK                | HLA-A*03:01, HLA-A*11:01, HLA-A*11:04, HLA-A*74:01 | 0.0076               |
| 4265          | VLSFCAFV                 | HLA-A*02:01, HLA-A*02:07                | 0.1701               |
| 4513          | YTMADLVLV                 | HLA-A*02:01, HLA-A*02:06, HLA-A*02:07 | 0.0262               |
| 4656          | YIKWDLIKY                | HLA-A*01:01, HLA-A*26:01, HLA-A*29:01, HLA-B*15:02, HLA-B*15:12, HLA-B*15:21, HLA-B*46:01 | 0.0287               |
| 4698          | ILHCANFNV                | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*02:07 | 0.0833               |
| 4723          | KIFVGVGF                | HLA-A*32:01, HLA-B*15:01, HLA-B*15:02, HLA-B*15:25, HLA-B*15:32 | 0.1614               |
| 4846          | YYRYNLPTM                | HLA-A*24:02, HLA-A*24:10               | 0.0097               |
| 4862          | FVVEVVDKY                | HLA-A*26:01, HLA-A*29:01, HLA-A*34:01, HLA-B*15:21, HLA-B*35:01, HLA-B*35:30, HLA-B*46:01 | 0.0859               |
| 5024          | MASLVLARK                | HLA-A*03:01, HLA-A*11:01, HLA-A*11:04, HLA-A*30:01, HLA-A*33:03, HLA-A*34:01, HLA-A*74:01 | 0.0282               |
| 5132          | FVNEFYAYL                | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*26:01, HLA-A*34:01, HLA-A*46:01 | 0.2400               |
| 5245          | LMIEFVSL                 | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*32:01, HLA-B*08:01, HLA-B*15:01, HLA-B*15:02, HLA-B*15:10, HLA-B*15:12, HLA-B*15:21, HLA-B*15:25, HLA-B*35:02, HLA-B*38:02, HLA-B*46:01 | 0.2427               |
| 5247          | IERFVSIA                 | HLA-B*13:01, HLA-B*37:01, HLA-B*40:01, HLA-B*40:02, HLA-B*40:06, HLA-B*41:01, HLA-B*44:03, HLA-B*52:01 | 0.0326               |
| 5250          | FVSLAIDAY                | HLA-A*01:01, HLA-A*26:01, HLA-A*29:01, HLA-A*34:01, HLA-B*15:02, HLA-B*15:21, HLA-B*35:01, HLA-B*35:05, HLA-B*35:30, HLA-B*46:01 | 0.1401               |
| 5273          | HLYLQYIRK                | HLA-A*03:01, HLA-A*11:01, HLA-A*11:04, HLA-A*74:01 | 0.0139               |
| 5614          | FAIGHLALY                | HLA-A*01:01, HLA-A*26:01, HLA-A*29:01, HLA-B*15:13, HLA-B*15:21, HLA-B*35:01, HLA-B*35:05, HLA-B*35:30, HLA-B*58:01, HLA-B*46:01 | 0.0918               |
| 5678          | YVFCTVNAL                | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*26:01, HLA-A*34:01, HLA-B*07:02, HLA-B*07:05, HLA-B*15:02, HLA-B*15:10, HLA-B*15:21, HLA-B*35:01, HLA-B*35:02, HLA-B*35:05, HLA-B*35:30, HLA-B*38:02, HLA-B*48:01, HLA-B*56:01, HLA-B*56:02, HLA-A*02:07, HLA-B*46:01 | 0.0778               |
Vaccines 2021, 9, 1459

Table 4. Cont.

| Start Residue | Peptide | HLA Class I Alleles | Immunogenicity Score |
|---------------|---------|---------------------|----------------------|
| 6070          | FKHILIPLMY | HLA-A*29:01, HLA-B*18:02 | 0.0065               |
| 6108          | VLWAHGFELa | HLA-A*02:01, HLA-A*02:06, HLA-A*02:07 | 0.3320               |
| 6506          | FELWAKRNII | HLA-B*40:01, HLA-B*40:02, HLA-B*40:06, HLA-B*41:01 | 0.0943               |
| 6585          | FRNARNGVL  | HLA-B*15:10, HLA-B*27:06 | 0.1343               |
| 6700          | HLGLAKR    | HLA-A*33:03, HLA-A*74:01 | 0.0599               |
| 6714          | FELEDFIPMb | HLA-B*13:01, HLA-B*15:10, HLA-B*18:01, HLA-B*18:02, HLA-B*37:01, HLA-B*38:02, HLA-B*40:01, HLA-B*40:02, HLA-B*40:06, HLA-B*41:01, HLA-B*44:03, HLA-B*48:01 | 0.3348               |
| 6748          | LLLDDFVEIA,b,c | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-B*52:01, HLA-A*02:07 | 0.2439               |
| 6848          | CQYLNTLTL | HLA-B*13:01, HLA-B*15:10, HLA-B*27:06, HLA-B*37:01, HLA-B*38:02, HLA-B*48:01, HLA-B*52:01 | 0.0312               |
| 6850          | YLNLTLLAV a,b | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*02:07 | 0.0762               |
| 6885          | WLPFTGILV  | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*02:07 | 0.0892               |
| 6978          | YKLMGFHFAW | HLA-B*18:01, HLA-B*18:02 | 0.0048               |
| 7019          | YVMHANYIF a | HLA-A*24:02, HLA-A*24:07, HLA-B*15:02, HLA-B*15:13, HLA-B*15:21, HLA-B*35:01, HLA-B*35:05, HLA-B*35:30, HLA-B*56:02, HLA-B*46:01 | 0.0822               |
| 7026          | IFWRNTNPIC | HLA-A*24:02, HLA-A*24:07, HLA-A*24:10 | 0.1423               |

a The peptide has been experimentally proven by T-cell assay and reported in IEDB; b The peptide has been experimentally proven by HLA binding and reported in IEDB; c Peptide has some degree of homology with human self-peptide; d The peptide existed only in 9.61% of delta variant isolates, whereas the rest had the mutant peptide.

Looking into detail about the immunogenicity score of the 65 peptides, the lowest score was 0.0048 (6978 YKLMGFHFAW6986) and the highest was 0.3348 (6714 FELEDFIPM6722). The most immunogenic peptide was already reported in IEDB as binder for HLA-B*40:01. In our prediction, 6714 FELEDFIPM6722 binds to 13 HLA Class I alleles (HLA-B*13:01, HLA-B*15:10, HLA-B*18:01, HLA-B*18:02, HLA-B*37:01, HLA-B*38:02, HLA-B*40:01, HLA-B*40:02, HLA-B*40:06, HLA-B*41:01, HLA-B*44:03, and HLA-B*48:01). The number of HLA alleles that bind to the peptides range from 2 (6978 YKLMGFHFAW6986 binds to HLA-B*18:01 and HLA-B*18:02) to 24 (899 WSMATYLF907 binds to HLA-A*01:01, HLA-A*24:02, HLA-A*24:07, HLA-A*24:10, HLA-A*29:01, HLA-A*32:01, HLA-A*13:01, HLA-B*15:02, HLA-B*15:12, HLA-B*15:13, HLA-B*15:17, HLA-B*15:21, HLA-B*15:25, HLA-B*15:32, HLA-B*18:01, HLA-B*18:02, HLA-B*35:01, HLA-B*35:05, HLA-B*35:30, HLA-B*52:01, HLA-B*56:07, HLA-B*57:01, HLA-B*58:01, and HLA-B*46:01). 899 WSMATYLF907, the most promiscuous peptide in our list, had also been reported in IEDB as an HLA binder, in particular to HLA-A*24:02.

3.6. Prediction of HTL Epitopes and Evaluation of IFN-γ Induction Capability

HTL epitopes from ORF1ab were predicted using netHLAIIpan 4.0 against a panel of 22 HLA Class II alleles as shown in Figure 3. As HLA Class II can accommodate longer peptides, the prediction was made for 15-mer peptides. The server generated 792 15-mer peptides as strong binders (≤1 percentile rank) for HLA Class II as shown in Figure 5. HLA-DRB1*15:02 (allele frequency of 0.2410), binds to the highest number of peptides (129), while HLA-DRB1*04:03 and DRB1*04:06 (allele frequency of 0.021 and 0.005, respectively) bind the lowest number of peptides (52). The top three most predominant HLA Class II alleles in the Indonesian population were HLA-DRB1*12:02 (allele frequency of 0.3680), HLA-DRB1*15:02 (0.2410), and HLA-DRB1*07:01 (0.1370). HLA-DRB1*12:02 binds 88 peptides and DRB1*07:01 binds 101 peptides.
Vaccines 2021, 9, x FOR PEER REVIEW 17 of 41

Figure 5. The number of predicted HTL epitopes that are presented by the HLA-DRB1 allele. NetHLAIIpan4.0 predicted 792 peptides bind to at least 1 HLA Class II with a strong binding affinity (≤1% percentile rank).

Peptide promiscuity (bind to many HLA alleles) is an essential criterion to be fulfilled for a successful vaccine design that can cover as large a population as possible. Out of 792 15-mer peptides, 102 of them bind to at least 5 alleles of HLA Class II and therefore were selected for further evaluation. Production of IFNγ by HTL is important for generation and differentiation of the CD8+ T-cell into a cell that has a full effector function, and for the induction of T-cell memory. Out of 102 peptides that were analyzed by the IFNγ prediction server, only 40 peptides have positive scores and are therefore short-listed for further downstream analysis (Table 5).

Table 5. List of 15-mer peptides predicted as promiscuous HTL epitopes and their IFNγ score.

| Start Residue | Epitope Sequence | HLA DRB1 Alleles | IFNγ Score |
|---------------|------------------|------------------|------------|
| 447           | NDNLEILQKEKVIN   | DRB1*12:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, DRB1*14:54, | 0.1311     |
| 448           | DNLLEILQKEKVIN   | DRB1*12:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, DRB1*14:54, | 0.0556     |
| 554           | TAQNSVRVLQKAAIT  | DRB1*12:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, DRB1*14:54, | 0.0684     |
| 736           | PKEIIFLEGETLPT   | DRB1*01:01, DRB1*12:02, DRB1*15:01, DRB1*15:02, DRB1*16:02, | 0.0771     |
| 1054          | PTVVVNAANVYLIK   | DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:54, DRB1*15:01, | 0.0917     |
| 1187          | VSSFLEMKSEKVEQ   | DRB1*04:01, DRB1*04:03, DRB1*04:05, DRB1*10:01, DRB1*10:06, | 0.0899     |
| 1211          | VKPFTTESKPSVEQR  | DRB1*08:03, DRB1*11:01, DRB1*13:02, DRB1*14:05, DRB1*14:07, | 0.3157     |
| 1349          | CKSAFYILPSIISNE  | DRB1*01:01, DRB1*04:01, DRB1*04:05, DRB1*10:01, DRB1*11:01, | 0.2898     |
| 1350          | KSAFYILPSIISNEK  | DRB1*01:01, DRB1*04:01, DRB1*04:03, DRB1*04:05, DRB1*14:07, | 0.3378     |
| 1355          | ILPSIISNEKQEILG  | DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, DRB1*14:07, | 0.4244     |
| 1356          | LPSIISNEKQEILGT  | DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, DRB1*14:07, | 0.3025     |
| 1357          | PSISNKEILGTVC    | DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, DRB1*14:54, | 0.5074     |
| 2944          | AYESLRPDTRYVLMD  | DRB1*03:01, DRB1*14:01, DRB1*14:04, DRB1*14:05, DRB1*14:54, | 0.3078     |
| 2945          | YESLRPDTRYVLMDG  | DRB1*03:01, DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, | 0.1649     |
### Table 5. Cont.

| Start Residue | Epitope Sequence | HLA DRB1 Alleles | IFNγ Score |
|---------------|------------------|------------------|------------|
| 2958          | DGSIQFPNTLEGS    | DRB1*04:02, DRB1*13:02, DRB1*15:01, DRB1*15:02, DRB1*16:02, | 0.2103     |
| 3815          | VSTQEFRYMNSQGLL | DRB1*01:01, DRB1*07:01, DRB1*09:01, DRB1*15:02, DRB1*16:02, | 0.0976     |
| 3944          | IAESFSSLPSYAAFA  | DRB1*01:01, DRB1*04:01, DRB1*10:01, DRB1*15:02, DRB1*16:02, | 0.0754     |
| 3945          | ASEFSSLPSYAAFA   | DRB1*01:01, DRB1*04:01, DRB1*10:01, DRB1*15:02, DRB1*16:02, | 0.3973     |
| 3951          | LPSYAAFATAEYE    | DRB1*04:01, DRB1*04:03, DRB1*04:05, DRB1*04:06, DRB1*08:03, | 0.0518     |
| 4457          | LIDSYFVVKRHFTSFN| DRB1*08:03, DRB1*11:01, DRB1*13:02, DRB1*14:01, DRB1*14:04, | 0.1304     |
| 4458          | IDSYFVVKRHFTSNY  | DRB1*08:03, DRB1*11:01, DRB1*13:02, DRB1*14:01, DRB1*14:04, | 0.1870     |
| 4560          | NPDLRIVYANLGERV  | DRB1*04:02, DRB1*08:03, DRB1*12:02, DRB1*15:01, DRB1*15:02, | 0.2299     |
| 4561          | PDILRIVYANLGERVa | DRB1*04:02, DRB1*08:03, DRB1*13:02, DRB1*15:01, DRB1*15:02, | 0.2616     |
| 4761          | KELIVYAADPMHAA   | DRB1*04:01, DRB1*04:02, DRB1*15:01, DRB1*15:02, DRB1*16:02, | 0.2258     |
| 4830          | KHHFFAQDNAAISD   | DRB1*01:01, DRB1*04:01, DRB1*10:01, DRB1*14:07, DRB1*16:02, | 0.4401     |
| 4933          | QMNKLKAYSAKNNRA  | DRB1*08:03, DRB1*10:01, DRB1*11:01, DRB1*13:02, DRB1*14:05, | 0.4044     |
| 4934          | MNLKVAYSAKNRAT   | DRB1*08:03, DRB1*10:01, DRB1*11:01, DRB1*13:02, DRB1*14:05, | 0.4019     |
| 4935          | NKLYAYSAKNRARTV  | DRB1*08:03, DRB1*11:01, DRB1*13:02, DRB1*14:05, DRB1*14:07, | 0.5938     |
| 5019          | PNMLRIMASLVLARKa | DRB1*01:01, DRB1*12:02, DRB1*14:04, DRB1*15:01, DRB1*15:02, | 0.3914     |
| 5717          | AKHYVYIDPAQLPA   | DRB1*04:01, DRB1*04:03, DRB1*04:05, DRB1*04:06, DRB1*08:03, | 0.1673     |
| 5775          | TVSALVYDNKLKAHK  | DRB1*03:01, DRB1*11:01, DRB1*13:02, DRB1*14:01, DRB1*14:04, | 0.3517     |
| 5776          | VSAALVYDNKLKAHKD | DRB1*03:01, DRB1*08:03, DRB1*11:01, DRB1*13:02, DRB1*14:01, | 0.2560     |
| 5777          | SALVYDNKLKAHKDK  | DRB1*03:01, DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, | 0.4910     |
| 5834          | VFISPYNSQNNAVASK | DRB1*01:01, DRB1*04:01, DRB1*04:02, DRB1*10:01, DRB1*15:01, | 0.2236     |
| 6046          | PTGYVDPNTNDFSR   | DRB1*04:01, DRB1*04:03, DRB1*04:05, DRB1*04:06, DRB1*08:03, | 0.0690     |
| 6454          | LENVAFNVNKGHFD   | DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, DRB1*14:07, | 0.0787     |
| 6726          | TVKYNIFTDAQTGSS  | DRB1*01:01, DRB1*04:01, DRB1*07:01, DRB1*09:01, DRB1*10:01, | 0.0871     |
| 7075          | KGLRLIENRRVVIS   | DRB1*04:02, DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, | 0.7895     |
| 7076          | GGLRLIENRRVVISS  | DRB1*04:02, DRB1*13:02, DRB1*14:01, DRB1*14:04, DRB1*14:05, | 0.7985     |
| 7077          | RGLRLIENRRVVISSD | DRB1*13:02, DRB1*14:01, DRB1*14:05, DRB1*14:07, DRB1*14:54, | 0.8026     |

*a The peptide has been experimentally proven by T-cell assay and reported in IEDB.
3.7. Conservancy Analysis

Epitopes conservancy among SARS-CoV-2 variants was the next criteria applied to the predicted 65 CTL and 40 HTL epitopes. The conservancy analysis was carried out using the IEDB epitope conservancy analysis tool against ORF1ab sequences from SARS-CoV-2 variants listed in Table 1. The duplicated sequences were removed before the analysis to avoid bias. The goal of the conservancy analysis was to identify epitopes having conservancy levels near to 100% across SARS-CoV-2 variants to be included in the VC.

IEDB T-cell epitope conservancy analysis revealed that the majority of the HTL and CTL epitopes were conserved. Out of 40 HTL epitopes, 26 of them had at least 95% conservancy within the variant and among different variants (Table S2). These 26 peptides were short-listed for downstream analysis. CTL peptides were conserved within each variant and across all variants, with the level of conservancy mostly above 97% (Table S1).

One of the exceptions is peptide 3137FWITIAYII3145 (binds to HLA-A*24:02, HLA-A*24:07, and HLA-A*24:10), which had heterogeneity in its sequence due to mutation F3137S. 3137FWITIAYII3145 was present only in 9.61% of the ORF1ab sequences of the delta variant B.1.617.2, while the rest of the sequences were 3137SWITIAYII3145. The changes in amino acid F3137S, however, did not result in the abrogation of the binding of the peptide into HLA molecules; instead, our analysis showed that mutant peptide had a stronger binding affinity (Table 6) toward HLA molecules. The peptide 3137FWITIAYII3145 is part of the NSP4 (size 500 amino acids) protein of SARS-CoV-2, which is a membrane protein that contains four transmembrane domains. The 375FWITIAYII383 peptide is located in the fourth transmembrane region of NSP4 [59]. Together with NSP3 and NSP6, NSP4 forms double-membrane vesicles that are needed for viral replication and transcription as well as for protecting the viral RNA from innate immune recognition [59–61]. NSP4 demonstrated high conservancy among the other coronaviruses, indicating its importance for viral replication, and during the pandemic of 2020 only one mutation (M324) was detected [16]. However, as the delta variant emerged and diverged into several clades, more mutations in NSP4 were detected including the F375S mutation, which is specific for clade E of the delta variant [62]. Comparing the binding affinity of the ancestral peptide versus the mutant peptide, one might argue that this mutation might not be beneficial for the virus as it can be easily recognized by T-cells. However, this would only happen if the population had the correct HLA alleles. Thus, the F3137S mutation might benefit viral replication, but since it occurred in clade E, it is assumed that the variant delta subclade E occurred in populations lacking HLA-A*24:02, A*24:07, and A*24:10.

Table 6. Comparison of binding affinity between the ancestral (FWITIAYII) and mutant (SWITIAYII) peptide. The calculation was made using NetCTLpan 1.1., which also predicted the peptide processing (proteasomal cleavage and TAP transport efficiency) inside the cell.

| Peptide        | Allele    | HLA         | TAP   | Cle | Comb | Aff(nM) | %Rank |
|----------------|-----------|-------------|-------|-----|------|---------|-------|
| FWITIAYII      | HLA-A*24:02 | 0.604 0.566 | 0.463 | 0.722 | 250.54 | 0.8    |
| SWITIAYII      | HLA-A*24:02 | 0.65 0.884 | 0.617 | 0.811 | 35.49  | 0.3    |
| FWITIAYII      | HLA-A*24:07 | 0.497 0.566 | 0.463 | 0.615 | 220.88 | 0.8    |
| SWITIAYII      | HLA-A*24:07 | 0.591 0.884 | 0.617 | 0.752 | 40.82  | 0.15   |
| FWITIAYII      | HLA-A*24:10 | 0.8 0.566 | 0.463 | 0.918 | 61.69  | 0.8    |
| SWITIAYII      | HLA-A*24:10 | 0.848 0.884 | 0.617 | 1.009 | 14.15  | 0.4    |

3.8. Comparison of Predicted Epitopes and Experimentally Proven Epitopes from IEDB

As a means to partially validate the prediction, the in silico identified epitopes were compared with the experimentally proven epitopes that are curated in IEDB. Out of 65 predicted CTL epitopes (9-mer), 26 matched with experimentally proven 9-mer epitopes by T-cell assay, 20 by HLA assay, and 10 by both T-cell and HLA assays (Table 4). Many of the experimentally proven epitopes are presented by only one HLA allele, such as HLA-A*02:01 or A*24:02. However, in our in-silico analysis, the peptides were predicted to bind to many other HLA alleles with strong binding affinity. Out of 40 predicted
15-mer HTL epitopes, 4 (5776 VSALVYDNKLKAHKD5790, 5019 PNMLRIMASLVLARK5033, 461 PDILRUYANGLERV5475, and 1350 KSAFYILPSIISNEK1364) matched with experimentally proven 15-mer epitopes by T-cell assay. All four HTL epitopes were reported in IEDB as positive for IFNγ ELISPOT assay, which confirmed the IFNγ prediction that was conducted in our in silico study.

3.9. Homology with Human Peptides

Homology of 40 HTL epitopes (15-mer peptides) with human peptides was conducted by analyzing the 9-mer peptide core component. That is because 9-mer (residue 4–12 of the 15-mer) is the core component of the peptide whose side chains interact with the HLA molecule and interact with the T-cell receptor. BlastP analysis showed that none of the HTL 9-mers were homologous with the 9-mer from the human protein. Therefore, we did not analyze the HTL 9-mers further but focused on the CTL 9-mer peptides only.

Homology analysis of the 65 CTL epitopes revealed that none have 100% homologies (9/9) with human peptides. However, one epitope has eight contiguous amino acids that matched 100% with the human peptides and six epitopes have seven contiguous amino acids that matched with the human peptides as shown in Table 7. NetCTLpan analysis of these human peptides showed that these self-peptides were predicted as T-cell epitopes with similar binding affinity to the HLA molecules that present the corresponding SARS-CoV-2 peptide (Table 7 compare with Table 4). SARS-CoV-2 peptides having high similarity to several human proteins have also been reported by other [63].

| Start | SARS-CoV-2 Peptide | Human Peptides | Human Proteins | HLA Allele Presenting the Human Peptide | IEDB Confirmation Assay |
|-------|--------------------|----------------|----------------|----------------------------------------|-------------------------|
| 1140  | HEVLLAPLL          | AEVLLAPLL      | HSVI binding protein (AAF76892.1) | HLA-B*37:01, HLA-B*38:02, HLA-B*40:01, HLA-B*40:02, HLA-B*40:06, HLA-B*41:01, HLA-B*44:03, HLA-B*44:03 | n.a.                     |
| 2784  | AIFYLITPV          | AIFYLITLV      | olfactory receptor, family 2, subfamily W, member 1, isoform CRA_b (EAX03180.1) | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06 | T-cell assay and HLA assay |
| 3582  | LLLTILTSL          | LLLTILTRP      | hCG2023968 (EAW49626.1) | non binder | HLA assay |
| 3684  | YASAVVLLI          | YASAVVLLG      | molybdenum cofactor biosynthesis protein 1 isoform 7 (NP_001345459.1) | non-binder | T-cell assay |
| 3752  | FLARGIVFM          | XCARGIVFM      | immunoglobulin heavy chain junction region (MOL38621.1) | cannot generate a similar peptide, since the sequence is at the N-terminal end of the protein. | T-cell assay and HLA assay |
| 5614  | FAIGLALYY          | SYIGLALYY      | immunoglobulin heavy chain junction region (MOJ91547.1) | HLA-A*29:01 | T cell assay |
| 6748  | LLDDFVEI           | IALDDFVEI      | Wolfram syndrome 1 (wolframin), isoform CRA_a (EAW82396.1) | HLA-A*02:06, HLA-B*52:01 | T-cell assay and HLA assay |
Interesting to note is the ORF1ab peptide 2784AIFYLITPV2792 matched with human peptide AIFYLITLV, which is derived from the olfactory receptor (EAX03180.1). Human peptide AIFYLITLV was predicted to be presented by HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, similarly to the SARS-CoV-2 peptide counterpart. It is possible that high homology will result in the activation of cross-reactive T-cells recognizing SARS-CoV-2 peptides to attack olfactory cells and cause of anosmia in some COVID-19 patients. The recent publication confirmed experimentally that epitope 2784AIFYLITPV2792 was recognized by T-cells from SARS-CoV-2 convalescent individuals having HLA-A*02:01 allotype [64]. It would be interesting to check the patient’s history of anosmia symptoms and whether the symptoms disappeared or persisted, due to the activation of self-reactive T-cells.

3.10. Epitope Cross-Reactivity with Human Peptides, Human Common Cold Coronaviruses (HCCs), or Other Ubiquitous Antigens

As shown in Table 7, seven SARS-CoV-2 ORF1ab peptides shared sequence similarities with human peptides. Cross-checking with the IEDB data, it was revealed that six out of seven SARS-CoV-2 ORF1ab peptides that were similar to human peptides were already experimentally confirmed and reported in IEDB (Table 7). One peptide was experimentally confirmed by HLA binding assay, two peptides were confirmed by T-cell assay, and three were confirmed by both T-cell and HLA binding assay. Here, we focused our analysis on the epitopes that had been confirmed by T-cell assay and checked whether or not the epitopes were recognized by SARS-CoV-2 convalescent individuals or healthy subjects who never experienced SARS-CoV-2 infection. Four ORF1ab peptides (5614FAIGLALYY5622, 3684YASAVVLLI3692, 6748LLLDDFVEI6872, and 3752FLARGIVFM3760) that matched with human peptides were recognized by T-cell from healthy individuals who have not been infected by SARS-CoV-2 (Table S3). As a comparison (Table S4), from 23 IEDB ORF1ab peptides that did not match with human peptides, only 7 were confirmed by T-cell assay using samples from healthy individuals who never experienced SARS-CoV-2 infection while the rest were detected in individuals previously infected by SARS-CoV-2. Several studies reported the presence of cross-reactive T-cells recognizing epitopes from SARS-CoV-2 in individuals that were never exposed to SARS-CoV-2 [25,65–69]. We then checked for the degree of homology between SARS-CoV-2 peptides versus human peptides and HCCs. In some instances, SARS-CoV-2 peptides shared greater homology with human peptides rather than with HCC peptides (Table S3).

The fact that the epitopes are similar to human self-peptides and the T-cells recognizing these peptides were mostly found in the healthy individuals without prior exposure to SARS-CoV-2, raises three possibilities. The first possibility is that T-cells responding to these peptides were primed by exposure to HCCs. The second possibility is that the assay picked up the signal and detected the presence of self-reactive T-cells in the circulation. Although the presence of highly self-reactive T-cells in the circulation is highly unlikely due to negative selection in the thymus, positive selection will permit T-cells to be slightly reactive toward self-antigens. One study reported that SARS-CoV-2 proteomes contain peptides similar to human proteomes and might able to trigger autoimmunity [70]. Table S4 shows SARS-CoV-2 peptides that did not have homology with human peptides. Some of these SARS-CoV-2 peptides (i.e., 1674YLATALLTL1682, 2787YLITPVHVM2795, 2786FYLITPVHV2794, and 3121FLAHQWMV3129) also did not have homology with HCC. Interestingly, these peptides were recognized by healthy individuals. These data suggest the third possibility by which the T-cells, recognizing the epitopes, are primed by the exposure to other ubiquitous antigens. A recent report suggested that such sequence homology exists between SARS-CoV-2 peptides and peptides from allergen proteins [71], malaria proteins [72], and antigenic proteins in BCG, OPV, MMR, and some other vaccines [73]. Perhaps sequence homology, in the context of 9-mer T-cell epitopes, between pathogens is more common than what was originally thought.

Sequence homology between SARS-CoV-2 peptides and HCC peptides (Tables S3 and S4) strongly supports the hypothesis that T-cells primed by previous HCC infection can recognize SARS-CoV-2. Whether having such cross-reactive T-cells in the circulation is beneficial...
and leads to better disease outcomes, or detrimental and leads to severe disease, is yet to be determined. In some individuals, the previous infection with HCC might protect them from severe disease, or even lead to asymptomatic infection. Our sequence analysis and cross-checking with IEDB data showed that peptide \( ^{2883}\text{FLPRVFSAV}^{2891} \), which shares homology with OC43 \( \text{FLRVVFSQV} \), was recognized by an individual with documented exposure to SARS-CoV2 but without evidence for disease (Table S4) [74]. Although the evidence that the individual had prior OC43 infection remains to be established, it suggested the potential protection from pre-existing T-cells primed by HCC infection.

### 3.11. Epitope Selection

Based on the criteria, such as highest percentile rank (<1%) in the prediction, epitopes promiscuity, immunogenicity, IFN\( \gamma \) induction ability, high conservancy across all variants, low entropy value, and the absence of homology with human peptides, seven CTL and five HTL epitopes were chosen to be included in the VC (Table 8). The epitopes were chosen so that a minimum number of epitopes could cover the largest population possible (accommodate all HLA alleles in the population).

**Table 8.** Seven CTL and five HTL epitopes chosen for the VC and the population coverage. Epitopes fulfilled the criteria such as highest percentile rank, high promiscuity, high immunogenicity, high IFN\( \gamma \) induction ability, conservancy across all variants, low entropy value, and the absence of homology with human peptides.

| Start Residue | Peptide and Entropy * | HLA Alleles Bind to the Peptides | Population Coverage |
|---------------|-----------------------|---------------------------------|---------------------|
| 899 | WSMATYYLF (0.083) | HLA-A*01:01, HLA-A*24:02, HLA-A*24:07, HLA-A*24:10, HLA-A*29:01, HLA-A*32:01, HLA-B*13:02, HLA-B*15:02, HLA-B*15:12, HLA-B*15:13, HLA-B*15:17, HLA-B*15:21, HLA-B*15:25, HLA-B*15:32, HLA-B*18:01, HLA-B*18:02, HLA-B*35:01, HLA-B*35:05, HLA-B*35:30, HLA-B*52:01, HLA-B*56:07, HLA-B*57:01, HLA-B*58:01, HLA-B*46:01 | Indonesia 94.80; Thailand 77.44; Germany 66.25; World 64.13 |
| 5678 | YVFCTVNAL (0.026) | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*26:01, HLA-A*34:01, HLA-B*07:02, HLA-B*07:05, HLA-B*15:02, HLA-B*15:10, HLA-B*15:21, HLA-B*35:01, HLA-B*35:02, HLA-B*35:05, HLA-B*35:30, HLA-B*38:02, HLA-B*48:01, HLA-B*56:01, HLA-B*56:02, HLA-A*02:07, HLA-B*46:01 | Indonesia 77.39; Thailand 75.05; Germany 72.07; World 65.66 |
| 5245 | LMIERFVSL (0.000) | HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*32:01, HLA-B*08:01, HLA-B*15:01, HLA-B*15:02, HLA-B*15:10, HLA-B*15:12, HLA-B*15:21, HLA-B*15:25, HLA-B*15:32, HLA-B*35:02, HLA-B*37:01, HLA-B*38:02, HLA-B*48:01, HLA-A*02:07, HLA-B*46:01 | Indonesia 63.65; Thailand 74.26; Germany 71.42; World 63.19 |
| 6714 | FELEDFIPM (0.037) | HLA-B*13:01, HLA-B*13:02, HLA-B*15:10, HLA-B*18:01, HLA-B*18:02, HLA-B*37:01, HLA-B*38:02, HLA-B*40:01, HLA-B*40:02, HLA-B*40:06, HLA-B*41:01, HLA-B*44:03, HLA-B*48:01 | Indonesia 51.64; Thailand 46.46; Germany 35.87; World 35.59 |
| 5024 | MASLVLARK (0.000) | HLA-A*03:01, HLA-A*11:01, HLA-A*11:04, HLA-A*30:01, HLA-A*33:03, HLA-A*34:01, HLA-A*74:01 | Indonesia 67.42; Thailand 55.82; Germany 40.12; World 40.42 |
| 6848 | CQYLNTLTL (0.000) | HLA-B*13:02, HLA-B*15:10, HLA-B*27:06, HLA-B*37:01, HLA-B*38:02, HLA-B*48:01, HLA-B*52:01 | Indonesia 21.20; Thailand 20.90; Germany 10.15; World 13.16 |
3.12. Population Coverage

Multi-epitope peptide-based vaccines that induce cell-mediated immunity need to be constructed from promiscuous epitopes to cover a large population since T-cells recognize antigen in the form of peptide complex with HLA molecules, and HLA is the most polymorphic genes in humans with allele frequency varying by ethnic groups. We used the IEDB population coverage analysis tool to calculate the coverage of each chosen epitope and the epitope set for Indonesia, Thailand, Germany, and the world population as shown in Table 8. Table 9 shows the population coverage for 12 chosen T-cell epitopes presented by HLA class I, class II, and class combined. The majority of the epitopes would be responded by the Indonesian people, which would recognize 8–9 epitopes hits/HLA combinations and 90% of the population would recognize a minimum of 6 epitopes/HLA combinations. A combination of these 12 chosen epitopes was shown to have good coverage not only for Indonesia (100%) but also for Thailand (100%), Germany (99.98%), and the world (99.88%). Hence these 12 epitopes were chosen as candidates for vaccine design.

### Table 9. Population coverage of the 12 chosen epitopes. A projected population coverage, average number of epitope hits/HLA combinations recognized by the population, and minimum number of epitope hits/HLA combinations recognized by 90% of the population.

| Population/Area | Class I | Class II | Class Combined |
|-----------------|---------|----------|----------------|
|                 | Coverage | Average | p90 |
| Germany         | 99.75%   | 3.89     | 2.54 3.54     |
| Indonesia       | 100.0%   | 5.66     | 4.1   99.68%  |
| Thailand        | 99.76%   | 4.82     | 2.9   98.69%  |
| World           | 98.77%   | 3.65     | 2.08  90.66%  |
| Average         | 99.57%   | 4.5      | 2.9   95.57%  |

* The entropy value in the bracket. For HTL epitopes the entropy values are for seven possible 9-mer core-peptides.
### Table 9. Cont.

| Population/Area | Class I | Class II | Class Combined |
|----------------|---------|----------|----------------|
|                | Coverage<sup>a</sup> | Average<sub>_Hit</sub><sup>b</sup> | pc90<sup>c</sup> | Coverage<sup>a</sup> | Average<sub>_Hit</sub><sup>b</sup> | pc90<sup>c</sup> | Coverage<sup>a</sup> | Average<sub>_Hit</sub><sup>b</sup> | pc90<sup>c</sup> |
| Standard deviation | 0.47 | 0.8 | 0.75 | 3.75 | 0.42 | 0.21 | 0.05 | 1.2 | 1.07 |

<sup>a</sup> Projected population coverage; <sup>b</sup> average number of epitope hits/HLA combinations recognized by the population; <sup>c</sup> minimum number of epitope hits/HLA combinations recognized by 90% of the population.

### 3.13. Vaccine Design

The vaccine (Figure 6) was constructed by combining five HTL and seven CTL epitopes using linkers such as GPGPG and AAG, respectively [36]. Linkers were used to facilitate the antigen processing inside the cell and to ensure that individual epitopes will be generated by the cell. β-defensin was incorporated using EAAAK linker at the N-terminal to increase the antigenicity and immunogenicity of the peptide-based vaccine. β-defensin will also act as a TLR4 ligand that will induce the maturation of antigen-presenting cells and the successful activation of T-cells in the lymph nodes.

*Figure 6.* Amino acid sequences of the VC. Beta defensin (was used as adjuvant, HTL epitopes, and CTL epitopes were connected using linkers EAAAK, GPGPG, and AAG.

### 3.14. Vaccine Antigenicity, Allergenicity, Toxicity, and Physicochemical Characteristics

The VC was predicted to be a probable antigen as the antigenicity score was calculated to be 0.4369 by VaxiJen 2.0 and non-allergenic as predicted by AllergenFP v.1.0. Expasy ProtParam tool calculated the physicochemical properties of the VC, composing of 212 amino acids and a molecular weight of 22.993 kDa. The theoretical pI was 9.39, which indicated that the VC is slightly basic. The estimated half-life of the VC in *Escherichia coli* in vivo, yeast in vivo, and mammalian red blood cells in vitro, is 10, 20, and 30 h, respectively. This indicated that the VC could be synthesized using these cell systems. The VC was predicted to be stable as the instability index was computed to be 32.23, thermostable as indicated by the aliphatic index of 84.34, and slightly hydrophobic as the GRAVY score was computed to be 0.065. The VC was evaluated for toxicity using Toxinpred that generated fragments of 10 amino acid lengths and predicted their toxicity (Table S5). All CTL and HTL epitopes components of the vaccine were non-toxic. Toxic peptides were predicted from the β-defensin part (residue 29–48), which is expected given the fact that β-defensin acts as an adjuvant.

### 3.15. Re-Analyze the VC for Epitopes Generation and Homology with Human Proteins and Microbiomes

The VC was re-analyzed using NetCTLpan1.1 and NetMHCIpan4.0 to check that the CTL and HTL epitopes used to design the vaccine will be processed and generated by the antigen-presenting cells. Further analysis was conducted to check that the new CTL and HTL epitopes that were generated did not have similarities with the human peptides.
and peptides from human microbiomes, which will induce autoimmunity, reduce vaccine immunogenicity, and disrupt immune homeostasis.

NetCTLPan1.1 analysis of the VC against 56 HLA Class I alleles revealed that 43 of 9-mer CTL epitopes can be generated from the vaccine (Table S6). All seven CTL epitopes that were used to construct the vaccine were generated, albeit not all of them were presented by the HLA alleles that were initially predicted to bind. However, this is mainly due to the protein size rather than the changes in binding affinity. The smaller the protein size, the lower the possibility that the epitopes will have a score <1% percentile rank. BlastP analysis against the human proteome showed some of the new epitopes are homologous (100% match) to human self-peptides; in particular, the epitopes from the β-defensin region. The other epitopes are only partially homologous (7/7 amino acid).

NetMHCIIpan4.0 analysis of the VC (Table S7) showed that all five HTL epitopes were generated (marked with *) along with extra new epitopes. The 9-mer peptide-binding core of all HTL epitopes was evaluated for sequence similarity with the human peptides. None of the HTL 9-mer epitopes were homologous (100% match) with human peptides, and only two 9-mer peptides were partially homologous (7/7 amino acid) (marked with ** in Table S7). Peptide FVSLAAGFE contains residue that matches with heptamer VSLAAGF from human protein hCG2019424 (sequence ID EAX10398.1). Peptide VISSDGPG contains residues that match with heptamer VISSDG from guanine nucleotide-binding protein (G protein) (sequence ID EAW53700.1).

None of the CTL and HTL 9-mers have sequence similarities with the peptides from human microbiomes as revealed by the analysis using PBIT (Table S8). It means that the vaccine construct should not disrupt host immune homeostasis.

3.16. In Silico Immune Simulation of the VC

The VC was analyzed using CimmSim for the ability to generate cell-mediated immunity CD8+ CTL and CD4+ HTL. As shown in Figure 7A, the level of the HTL population increased to around 4000 (cells/mm3) after the first dose of vaccine was administered. The number of HTL increased to 10,200 after the second dose of vaccine was given, and 9800 after the third dose. The increase in the number of HTL was accompanied by an increase in the level of HTL memory cells, where the level remains high at 600 after 300 days. The HTLs induced by the vaccine are all in the active, duplicating, and resting state, with no formation of an anergic state (Figure 7B). The absence of anergic T-cells is a good sign that the VC provides enough signal for the TLR and other PRR to sufficiently activate and induce the maturation of dendritic cells.

The level of CTL increased up to 1150 cells/mm3 upon administration of vaccine’s first dose (Figure 7C) and then fluctuated between 1055 cells/mm3 at the lowest and 1130 cells/mm3 at the highest. Administration of the first dose of vaccine increased the level of active state CTL to 1050 cells/mm3, which plateaued for 100 days before eventually declining and shifting into the resting state (Figure 7D). The fact that all CTL were found as active, duplicating, and resting-state cells, with no detectable level of anergic cells, indicated that the vaccine can induce dendritic cells maturation and expression of costimulatory molecules, which are needed for successful T-cell activation.

The vaccine did not induce any changes in the number of NK cells population as shown in Figure 7E where the number of NK cells fluctuated between 310 and 380 cells/mm3. Each vaccine dose administration induced an increase in the number of dendritic cells that internalize and present the antigen on both HLA Class I and II (Figure 7F). However, the vaccine did not increase the number of active dendritic cells as the population remains constant at 25 cells/mm3 throughout the simulated period (350 days). Aside from dendritic cells, the number of macrophages that internalized and presented the antigen on HLA Class II also increased at each dose of vaccine administration (Figure 7G). The number of active and resting macrophages increased concomitantly until the antigens are no longer be detected; at which time, the number of active macrophages declined, and resting macrophages increased.
At each vaccine dose administration, the level of cytokines, notably IFN\(\gamma\), is significant (410,000 ng/mL, 400,000 ng/mL, and 375,000 ng/mL at the first, second, and third dose, respectively) (Figure 7H). The production of IFN\(\gamma\) confirmed that the selected epitopes in the VC were able to induce Th1 cells, which are needed for the immune responses against viral infection. IL-2 was also produced as a response to the vaccine dose administration. IL-2 is an autocrine signaling protein produced by activated T-cell and acts as a T-cell growth factor. The presence of IL-2 is a good indication that the vaccine will induce T-cell clonal expansion.

Figure 7. The immune simulation analysis of the VC: (A) Population of HTL. (B) The population of different states of HTL. (C) population of CTL. (D) Population of different states of CTL. (E) Population of NK cells. (F) Population of different states of dendritic cells. (G) Population of different states of macrophages. (H) Level of cytokines and interleukins produced in responses to vaccine.
growth factor. The presence of IL-2 is a good indication that the vaccine will induce T-cell clonal expansion.

3.17. Secondary Structure and Tertiary Structure of Vaccine Construct

The secondary structure of the VC was predicted based on its amino acid sequences (Figure 8A) by SOPMA and the tertiary structure was predicted by RAPTOR X. SOPMA server predicts the secondary structure based on the multiple alignments of protein sequences of known structures. The VC had 212 residues of which mainly 95 residues were predicted to adopt the α-helix (44.81%), followed by 59 residues as a random coil (27.83%), 47 residues as an extended strand (22.17%), and only 11 residues were observed in β-turn (5.19%) (Figure 8B). The location and propensity of the secondary structure are shown in Figure 8C,D. A different method was employed to predict the tertiary structure of the VC (Figure 8E). RAPTOR X employed a deep learning method to predict the tertiary structure based on the inter-residue distance distribution of a protein, which worked best for predicting a protein structure that does not have many sequences homology. Overall model quality, indicated by z-score, was generated by ProSA-web, which is a web-based protein structure analysis. Since the size of the VC is 212 amino acids, the z-score should fall between −1 and −10, according to the plot. The z-score of the VC is −7.25, which fell within the range of conformational parameters of native proteins.

3.18. Molecular Docking of the VC with TLR4

The association of the antigen molecule with the immune receptor is an essential step for the appropriate activation of the immune responses. Toll-like receptor (TLR) is a pathogen recognition receptor on the surface of the immune cells such as dendritic cells that are important for their respective maturation process. Upon maturation, dendritic cells will be able to migrate from the tissue to the lymph nodes and present the peptide-HLA complex along with costimulatory molecules to activate naïve T-cells. Therefore, molecular docking analysis was performed to analyze the interaction between TLR4 and the VC. HDOCK was employed to generate information about the interacting residues on TLR4 and the VC. The PDB files of TLR4 (3FXI) and the VC generated by RAPTOR X was used as input files for prediction. HDOCK docking simulation generated several models with the top 10 models are listed in Table S9. The best model was model 1 with a docking score of −283.87, which reflected good interactions between the VCs and TLR4 (Table S10). The interaction between the VC and TLR4 was also simulated using ClusPRO by generating a PDB file of the complex for both the TLR (receptor) and the vaccine (ligand). The input files for ClusPRO were the PDB ID of the TLR4 (3FXI) and the PDB file of the VC, which was generated previously by RAPTOR X. The PDB model of the complex between TLR4 and the VC generated from ClusPRO was then used as input for the PDBind to generate the model and calculate the protein–protein interaction parameters. The model of the complex between TLR4 and the VC is shown in Figure 9. TLR4 is shown in the purple color, while the VC is shown in the red color, as shown in Figure 9A. The complex was formed via the interaction of 27 residues of TLR4 and 24 residues of the VC (Figure 9B). As expected, 16 out of 24 residues in the VC were from the β-defensin, as TLR4 ligand (Figure 9C). The interface area was 1192 Å² and 1233 Å² for TLR4 and the VC, respectively. It was observed that the interaction between residues was composed of 12 hydrogen bonds and 8 salt bridges, indicating good docking interaction, which corroborated the docking score generated previously by HDOCK (Table S9). Ramachandran plot and Procheck results for the complex between TLR4 and the VC showed 70.9% amino acids were in the most favored region and 26.7% in the additional allowed region, 0.5% in the generously allowed region, and only 1.8% in a disallowed region (Figure 9D). Even though less than 90% amino acids were in the most favored region, it is predicted that the complex between the VC and TLR4 would still be generated and that immune responses to the VC will still be induced, as shown by the CimmSim analysis results.
3.18. Molecular Docking of the VC with TLR4

The association of the antigen molecule with the immune receptor is an essential step for the appropriate activation of the immune responses. Toll-like receptor (TLR) is a pathogen recognition receptor on the surface of the immune cells such as dendritic cells that are important for their respective maturation process. Upon maturation, dendritic cells will be able to migrate from the tissue to the lymph nodes and present the peptide-

3.19. Molecular Docking Simulation of Peptide Binding to HLA-A*24:02 and HLA-A*24:07

WSMATYYLF has been reported in IEDB [24] and experimentally proven as an HLA-A*24:02 binder [75], and immunogenic, in the T-cell assay [64]. However, in this study, we predicted that WSMATYYLF is highly promiscuous and has high population coverage as shown in Table 8. WSMATYYLF binds to 23 other HLA Class I alleles including
HLA-A*24:07. Since HLA-A*24:07 is very important for Indonesian and other Southeast Asia populations, we conducted a molecular docking analysis to confirm that peptide WSMATYYLF will bind to HLA-A*24:07. The results show that in principle, WSMATYYLF binds equally well to both HLA-A*24:02 and HLA-A*24:07 (Figure 10A,B), albeit with a slightly different binding mode as reflected in the amino acid residues involved in the binding (Figure 10C,D).

**Figure 9.** Interaction analysis of the VC and TLR4. (A) The tertiary structure model of the complex between TLR4 (purple) and the VC (red). (B) Diagram of interaction between the VC and TLR4 (red = salt bridges, blue = H-bonds, striped line = non-bonded contacts). (C) Residues involved in forming the complex. (D) Ramachandran plot of the interaction model showing the number of residues in the most favored region and less favored region.
non-bonded contacts). (C) Residues involved in forming the complex. (D) Ramachandran plot of the interaction model showing the number of residues in the most favored region and less favored region.

3.19. Molecular Docking Simulation of Peptide Binding to HLA-A*24:02 and HLA-A*24:07

WSMATYYLF has been reported in IEDB [24] and experimentally proven as an HLA-A*24:02 binder [75], and immunogenic, in the T-cell assay [64]. However, in this study, we predicted that WSMATYYLF is highly promiscuous and has high population coverage as shown in Table 8. WSMATYYLF binds to 23 other HLA Class I alleles including HLA-A*24:07. Since HLA-A*24:07 is very important for Indonesian and other Southeast Asia populations, we conducted a molecular docking analysis to confirm that peptide WSMATYYLF will bind to HLA-A*24:07. The results show that in principle, WSMATYYLF binds equally well to both HLA-A*24:02 and HLA-A*24:07 (Figure 10A,B), albeit with a slightly different binding mode as reflected in the amino acid residues involved in the binding (Figure 10C,D).

4. Discussion

Adaptive immune responses, both humoral and cellular are important to combat viral infection. Humoral immunity, mediated by antibodies produced by B-cells will bind to the virus and hence prevent virus entry into the cells. Cellular immunity mediated by T-cells will kill the infected cells, and hence remove the viral reservoir so that the infection to other cells will be prevented.

In SARS-CoV-2 infection, however, available reports generally suggest a rapid decrease in the SARS-CoV-2-specific antibodies [76–79]. Confirmed by a longitudinal study showing the level of neutralizing antibodies declines over time after infection [80]. Moreover, a high virus mutation rate resulting in the emergence of SARS-CoV-2 variants, which have different antigenic profiles compared to the ancestral virus, could lead to viral escape from neutralizing antibodies elicited previously by vaccination (vaccine breakthrough) or natural infection (re-infection) [81]. On the other hand, T-cell responses could last up to 10 months after infection [82]. On top of that, intriguing data shows that host protection against COVID-19 could be mediated solely by T-cells. This is evident in some COVID-19 patients who have hematological malignancy comorbidity and therefore need to receive anti-CD20 therapy. Anti-CD20 therapy is part of the treatment for hematological malignancy [83] and autoimmune disorders like multiple sclerosis [84], which results in the depletion of B-cells, and hence these patients can not mount an antibody response. However, despite the lower
level of IgG in these patients, SARS-CoV-2 specific T-cell responses were detected, and the level was associated with good clinical outcomes [85]. The data suggests that T-cells play a significant role in protection in the situation where the neutralizing antibody is not present.

Preexisting T-cell immunity could ameliorate progression to severe COVID-19 as the early and robust T-cell responses to SARS-CoV-2 have been associated with less severe diseases [86]. In addition, patients with mild COVID-19 have been shown to have enriched CD8⁺ T cells specific for conserved epitopes across HCCs [87]. Altogether, these advocate for a T-cell oriented strategy for COVID-19 vaccines [88]. Knowledge and experiences from the other two zoonotic coronaviruses (CoV)-SARS-CoV-1 and MERS-CoV have confirmed the importance of T-cell immunity in the recovery and long-term protection from coronavirus infections [89–91]. Moreover, data from studies on humoral immunity to SARS-CoV-1 demonstrated that antibody responses were short-lived, whereas memory T-cell responses were long-lasting that could be detected at least 17 years after infection [68].

T-cells recognize peptides, derived from the pathogen, which are presented as a complex with the HLA molecule. The peptide, termed epitope, is usually 8–10 amino acids long for presentation by HLA Class I, and 15–20 amino acid long for HLA Class II. Each of the peptide–HLA Class I and –Class II complex is recognized by CD8⁺ and CD4⁺ T-cells, respectively. The HLA molecule, also known as HLA (human leukocyte antigen) in humans, is polymorphic. This polymorphism resulted in many different HLA alleles existing within the human population [92] and each population can be characterized by the different frequencies in the HLA allotypes. As an example, HLA-A*02:01 is predominant in the Caucasian population with allele frequency up to 40%, but only around 6% in the Indonesian population. On the other hand, HLA-A*24:07 is very common in the Indonesian population with an allele frequency of around 26%, but less than 1% in the Caucasian population. As the HLA molecule presents peptide antigen to T-cells, the type of peptide and strength of peptide–HLA association differs among distinct populations, as well as among racial and/or ethnic groups. Thus, each population might have preferences toward specific peptide epitopes to invoke T-cell mediated immunity.

Several CD4⁺ and CD8⁺ T-cell epitopes have been identified for SARS-CoV-2 and the data are curated in IEDB. Most of the identified T-cell epitopes were limited to several HLA allotypes that are predominant in the Caucasian population, such as HLA-A*02:01, whereas there were no data about peptides that were presented by HLA-A*24:07. Therefore, in this study, we aimed to identify the most promiscuous T-cell epitopes from SARS-CoV-2 to be used in the vaccine formulation for the world population while still considering the HLA alleles predominant in Indonesia that are not yet well studied. An in silico study identifying T-cell epitopes presented in the South American population has also been conducted by reviewing the HLA alleles frequencies in those countries [93].

There have been several reports employing immunoinformatics to identify T-cell epitopes and formulate a vaccine for SARS-CoV-2 infection. PubMed search using keywords ‘peptide-based vaccine’, ‘SARS-CoV-2’, and ‘immunoinformatics’ conducted on 14 October 2021 resulted in 15 research articles [94–108]. In this study, we made a prediction based on the HLA alleles that are present with at least 5% frequency in the Indonesian population. The majority of these HLA alleles have not been well studied, not only for the SARS-CoV-2 T-cell epitopes but also for other infectious agents, and hence no experimental data were available. In this analysis, we included some HLA alleles of the Thai population as well as HLA alleles included in the study of SARS-CoV-2 T-cell epitopes conducted in Germany [25]. In total, 56 HLA Class I and 22 HLA Class II alleles were covered in this study. Given that one individual can have 6 types of HLA class I and 2 types of HLA DRB1, by selecting these 78 alleles, it is estimated that 99% of people in the world have at least one HLA class I allele and 90% have one HLA Class II allele listed here; therefore, the vaccine construct could cover a large proportion of the world’s population.

We focused our search on promiscuous T-cell epitopes in the ORF1ab polyproteins since they would be beneficial for vaccine population coverage. Several studies support the utilization of ORF1ab as a vaccine target. A study by Gangaev et al. (2021) showed
that ORF1ab contains an immunodominant epitope restricted by HLA-A*01:01 and the epitope-specific CD8+ T-cell was detectable up to 5 months after recovery from critical and severe COVID-19 diseases [109]. Other studies [69,110] also confirmed that ORF1ab is the most immunogenic region of SARS-CoV-2 and contains the majority of the highly conserved immunodominant epitopes. Looking at the number of ORF1ab T-cell epitopes in the IEDB data (Table 2), it is evident that ORF1ab contains immunogenic epitopes that could be used for vaccine development.

ORF1ab is quite conserved as shown by entropy analysis. The high conservancy could be due to the function of ORF1ab as replicase enzymes that are needed for the virus to successfully replicate inside the host cells. ORF1ab is also the first protein to be synthesized by the infected cells [10], therefore having T-cells that are primed to recognize epitopes from ORF1ab will be beneficial for early viral clearance. Since ORF1ab contributes the highest numbers of the experimentally confirmed immunodominant epitopes, a detailed evaluation of these T cell epitopes for promiscuity and conservancy, which is important for vaccine design, will thus be possible. Our immunoinformatics analysis using NetCTLpan predicted 1132 CTL peptides and NetMHCIIpan predicted 792 HTL peptides that bind, respectively, to at least 1 HLA Class I and 1 HLA Class II allele with the percentile rank less than 1%, minimizing the false-positive results.

The predicted peptides were evaluated further using several criteria such as immunogenicity, IFNγ inducing ability, promiscuity in binding to HLA alleles, conservancy across all SARS-CoV-2 variants, low entropy value, and non-homology with the human peptides and human microbiome peptides. In the end, seven CTL and five HTL epitopes were chosen to be incorporated in the VC. The VC covers the entire Indonesian and Thai population (100.00%) and a little less than 100.00% for Germany and the entire world population (>99.9%). In this study, the VC was evaluated further and fulfilled criteria, such as good antigenicity, non-allergenicity, and non-toxicity, and had good physicochemical characteristics, such as pI, stability, half-life, and GRAVY score. Similar approaches have already been used by previous studies to obtain peptides as vaccine candidates and for evaluation of vaccine physicochemical properties, as reported in the review by Sohail et al. (2021) [111].

The vaccine should not disrupt immune homeostasis or induce autoimmunity; therefore, in this study, we evaluated the VC for similarity with human peptides and human microbiomes. We used the VC sequences as input for NetCTLpan and NetMHCIIpan and obtained the list of potential peptides to be generated with percentile rank <1%. The results showed that all SARS-CoV-2 CTL and HTL epitopes that were used to construct the vaccines were indeed generated. However, other new extra CTL and HTL epitopes were also generated. These epitopes encompassed the peptide linkers at the junctional region between the original HTL and CTL epitopes. The generation of these extra epitopes has not previously been reported by others. While the generation of these extra epitopes cannot be avoided, we need to check whether the sequence of extra epitopes is homologous with the human peptides or human microbiomes. The BlastP analysis and PBIT analysis of these new CTL and HTL epitopes showed no similarity with the human peptides and human microbiomes, which confirmed the safety profile of the VC.

The safety profile is not the only requirement for a vaccine. The vaccine component should be able to interact with the receptor on the surface of the immune cells to generate appropriate immune responses. The interaction between the vaccine and the TLR4 was evaluated in this study. Engagement of TLR on the surface of dendritic cells with the ligand will ensure the proper maturation of the dendritic cell. Mature dendritic cell will be able to process the vaccine antigen, and then present the peptide–HLA complex to be recognized by T-cells as the signal1. Mature DC will also upregulate the CD80/CD86 molecules that will engage CD28 on the T-cell, which constitutes the required signal 2 for T-cell activation. The molecular docking simulation of the VC and TLR4 revealed that there are sufficient interactions between the two molecules to induce robust immune responses (Figure 9). This corroborated the immune simulation analysis results (Figure 7), which show the generation
of CTL and HTL responses upon vaccine administration along with the production of cytokines such as IFNγ and IL-2.

Within our VC, \textit{899WSMATYYLF} is the most promiscuous peptide that binds to 24 HLA Class I alleles, covering 94.80%, 77.44%, 66.25%, and 64.13% of Indonesia, Thailand, Germany, and the world population, respectively. \textit{899WSMATYYLF} has been reported in IEDB by HLA binding assay to HLA-A*24:02 [75] and T-cell assay using samples from an A*24:02 positive individual [64]. We performed the docking between peptide \textit{899WSMATYYLF} and HLA-A*24:07, which is the most predominant allele in the Indonesian population. So far, there are no experimental data of SARS-CoV-2 peptide that is represented by HLA-A*24:07. Despite its importance for the Indonesian and Southeast Asian populations, the HLA-A*24:07 is less studied as compared to HLA-A*24:02. In IEDB, there is only one pathogen peptide reported to be presented by HLA-A*24:07 [112]. Therefore, it is interesting to analyze the interaction between HLA-A*24:07 with the immunogenic peptide of SARS-CoV-2 (\textit{899WSMATYYLF}). From the docking analysis it is shown that the best model of HLA-A*24:07 with peptide \textit{899WSMATYYLF} has a more accuracy compared with HLA-A*24:02, suggesting that the peptide can potentially be presented by HLA-A*24:07, thus confirming our CTL epitope prediction.

5. Conclusions

T-cells recognize infected cells based on the complex of a pathogenic peptide and a HLA molecule. High polymorphism of the HLA gene ensures that any antigens can be presented to the immune system. However, the difference in HLA allotypes among different populations greatly affects the characters of adaptive immune responses against viral diseases and vaccines. These differences are evident between the Southeast Asian and European populations. Thus, regarding the COVID-19 pandemic, the identification and characterization of conserved SARS-CoV-2 T-cell epitopes across different HLA allotypes provide wide-ranging applications for diagnostic, prophylactic, and therapeutic developments. A vaccine applying conserved SARS-CoV-2 epitopes that induce both memory CD8+ and CD4+ T-cell responses across different populations with various HLA allotypes might represent a promising tool to end the public health and economic burdens due to the COVID-19 pandemic.

The current study generated data about SARS-CoV-2 ORF1ab T-cell epitopes and their characteristics, such as the epitopes conservancy; HLA-binding promiscuity; and the level of homology with peptides from human common cold coronaviruses, human self-proteins, and microbiomes. Those characteristics are important for the development of a peptide-based vaccine that induce T-cell responses. T-cells target the antigens originating from all proteins of SARS-CoV-2, including ORF1ab. ORF1ab is intrinsically conserved because it is important for virus replication, and therefore not easily mutated. Vaccines based on the evolutionarily stable protein is beneficial because it will work against all variants of SARS-CoV-2. The current study nominated 12 conserved and promiscuous epitopes to be used in the vaccine development that will cover the majority of the Indonesian and the world population. One epitope in particular, \textit{899WSMATYYLF}, was predicted to bind to HLA-A*24:07, which is the HLA allele predominant in the Indonesian population.

We highlighted Indonesia in this study since the HLA background of the population is different to that of the Caucasian population, as shown in Figure 3. HLA-A*24:07 is not very well studied and no data are available about SARS-CoV-2 T-cell epitopes associated with this HLA. The in silico data generated in this study should be followed by wet-lab experiments to map T-cell epitopes that will be recognized by COVID-19 convalescent individuals from Indonesia. Such a study has not previously been conducted, even though the allele frequency for HLA-A*24:07 is significantly high (0.26) and Indonesian (population of 277 million) is the fourth largest population in the world, and is also affected by the pandemic.

The study also generated other interesting findings related to the cross-reactive epitopes between SARS-CoV-2 and human proteins. Epitope \textit{2784AIFYLITPV} matched
with the human peptide AIFYLITLV, which is derived from the olfactory receptor. We hypothesized that epitope similarity might contribute to the anosmia symptoms in some COVID-19 patients. Experimental validation is needed to test the epitopes and the characteristics of T-cells recognizing the epitopes. The data generated might entangle the molecular mechanism of anosmia in some patients.

Taken together, the peptides reported here will provide more insight into the cellular-mediated immune responses against SARS-CoV-2 in populations with different genetic backgrounds and environments that could bring novel ideas for the development of COVID-19 vaccines and immune monitoring, which could be effective across different populations worldwide.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/vaccines9121459/s1. Table S1: Conservancy of predicted CTL epitopes among the SARS-CoV-2 variants. Row 1 contains information about the name of the variants according to the WHO, the Pango lineage of the variants, and the number of retrieved sequences in the bracket. The duplicated sequences were removed before the analysis and the percentage of the conservation was calculated based on the number of the unique sequences only, in which the proportion was shown in the bracket. Table S2: Conservancy of predicted HTL epitopes among the SARS-CoV-2 variants. Row 1 contains information about the name of the variants according to the WHO, the Pango lineage of the variants, and the number of retrieved sequences in the bracket. The duplicated sequences were removed before the analysis and the percentage of the conservation was calculated based on the number of the unique sequences only, in which the proportion was shown in the bracket. Table S3: Five out of 7 SARS-CoV-2 peptides that match with the human peptides were reported in IEDB as experimentally confirmed by T-cell assay. However, 4 peptides were recognized by T-cells from healthy individuals who have not been infected by SARS-CoV-2. This table shows the comparison of the degree of homology of SARS-CoV-2 peptides versus peptides from human proteomes and versus peptides from HCCs (229E, HKU, NL63, and OC43). For homology with HCC, only homology of > 60% was considered. Table S4: SARS-CoV-2 peptides that do not have homology match with the human peptides were reported in IEDB as experimentally confirmed by T-cell assay. The majority of these peptides were recognized by T-cells from individuals who were infected by SARS-CoV-2. Table S5: Toxicity of the VC. ToxinPred scans for fragments of 10 amino acid length and predicts their toxicity. Only residue 29–48 which is part of the β-defensin adjuvant that contains toxic fragments of 10-mer peptides. Table S6: VC evaluation for possible CTL epitopes that will be generated and homology of new epitopes with human peptides. Table S7: VC evaluation for possible HTL epitopes that will be generated and the possibility of new epitopes homology with human peptides. Table S8: Non-homology analysis of VC peptides against gut microbiota proteomes using PBIT server. All 43 of 9-mer CTL epitopes (left panel) and 17 of 9-mer core peptides of HTL epitopes (right panel) that were generated from the VC were input into the PBIT server, which will calculate the similarity of peptide sequences with the sequences from the gut microbiomes. Table S9: Summary of the Top 10 models generated by HDOCK for interaction between TLR4 and the VC. Table S10: Receptor–ligand interface residues pair for Model 1.

**Author Contributions:** Conceptualization, M.G.; data curation, M.G, B.P. S. and D.A.; formal analysis, M.G., B.P. S. and D.A.; funding acquisition, M.G., D.A. and S.A.; investigation, M.G., B.P.S., D.A. and S.A.; methodology, M.G., B.P. S. and D.A.; writing—original draft, M.G.; writing—review and editing, M.G., B.P.S., D.A. and S.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi Republik Indonesia (Ministry of Education, Culture, Research and Technology, Republic of Indonesia), Southeast Asia-Europe Joint Funding Scheme for Research and Innovation, contract grant number 356/E4.1/AK.04.PT/202.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Khan, S.; Siddique, R.; Shereen, M.A.; Ali, A.; Liu, J.; Bai, Q.; Bashir, N.; Xue, M. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. J. Clin. Microbiol. 2020, 58, e00187-20. [CrossRef]

2. Mo, P.; Xing, Y.; Xiao, Y.; Deng, L.; Zhao, Q.; Wang, H.; Xiong, Y.; Cheng, Z.; Gao, S.; Liang, K.; et al. Clinical Characteristics of Refractory COVID-19 Pneumonia in Wuhan, China. Clin. Infect. Dis. 2020, ciaa270. [CrossRef] [PubMed]

3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 21 September 2020).

4. Satuan Tugas Penanganan COVID-19 Peta Sebaran COVID-19. Available online: https://covid19.go.id/peta-sebaran (accessed on 26 September 2021).

5. Zhou, P.; Yang, L.-X.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature 2020, 579, 270–273. [CrossRef]

6. Cascella, M.; Rajnik, M.; Aleem, A.; Dulebohn, S.C.; di Napoli, R. Features, Evaluation, and Treatment of Coronavirus (COVID-19) (Updated 2021 Sep 2). In StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. Available online: https://www.ncbi.nlm.nih.gov/books/NBK554776/ (accessed on 2 September 2021).

7. Hu, B.; Guo, H.; Zhou, P.; Shi, Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021, 19, 141–154. [CrossRef]

8. Chen, Y.; Liu, Q.; Guo, D. Emerging Coronaviruses: Genome Structure, Replication, and Pathogenesis. J. Med. Virol. 2020, 92, 418–423. [CrossRef]

9. Yoshimoto, F.K. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2 or n-COV19), the Cause of COVID-19. Protein J. 2020, 39, 198–216. [CrossRef] [PubMed]

10. Yadav, R.; Chaudhary, J.K.; Jain, N.; Chaudhary, P.K.; Khanra, S.; Dhamija, P.; Sharma, A.; Kumar, A.; Handu, S. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells 2021, 10, 821. [CrossRef]

11. Micochova, P.; Kemp, S.A.; Dhar, M.S.; Papa, G.; Meng, B.; Ferreira, I.A.T.M.; Datir, R.; Collier, D.A.; Albecka, A.; Singh, S.; et al. SARS-CoV-2 B.1.617.2 Delta Variant Replication and Immune Evasion. Nature 2021, 599, 114–119. [CrossRef]

12. Toyoshima, Y.; Nemoto, K.; Matsumoto, S.; Nakamura, Y.; Kiyotani, K. SARS-CoV-2 Genomic Variations Associated with Mortality Rate of COVID-19. J. Hum. Genet. 2020, 65, 1075–1082. [CrossRef]

13. Korber, B.; Fischer, W.M.; Gnanakaran, S.; Yoon, H.; Theiler, J.; Abfalterer, W.; Hengartner, N.; Giorgi, E.E.; Bhattacharya, T.; Foley, B.; et al. Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus. Cell 2020, 182, 812–827. [CrossRef] [PubMed]

14. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html (accessed on 23 September 2021).

15. World Health Organization. COVID-19 Vaccine Tracker and Landscape. Available online: https://www.who.int/publications/m/item/draft-landscape-of-COVID-19-candidate-vaccines (accessed on 24 September 2021).

16. Vilar, S.; Isom, D.G. One Year of SARS-CoV-2: How Much Has the Virus Changed? Europe. Viruses 2021, 9, 418–423. [CrossRef]

17. Khan, A.M.; Hu, Y.; Miotto, O.; Thesavagayam, N.M.; Sukumaran, R.; Abd Raman, H.S.; Brusic, V.; Tan, T.W.; Thomas August, J. Analysis of Viral Diversity for Vaccine Target Discovery. BMC Med. Genom. 2017, 10, 78–92. [CrossRef]

18. Larsson, A. AliView: A Fast and Lightweight Alignment Viewer and Editor for Large Datasets. Bioinformatics 2014, 30, 3276–3278. [CrossRef]

19. Miller, M.A.; Pfeiffer, W.; Schwartz, T. Creating the CIPRES Science Gateway for Inference of Large Phylogenetic Trees. In Proceedings of the Gateway Computing Environments Workshop (GCE), New Orleans, LA, USA, 14 November 2010; pp. 1–8.

20. Miotto, O.; Heiny, A.; Tan, T.W.; August, J.T.; Brusic, V. Identification of Human-to-Human Transmissibility Factors in PB2 Proteins of Influenza A by Large-Scale Mutational Information Analysis. BMC Bioinform. 2008, 9, S18. [CrossRef]

21. Gonzalez-Galarza, F.F.; Martini, S.; Cantrell, J.R.; Wheeler, D.K.; Sette, A.; Peters, B. The Immune Epitope Database (IEDB); 2018 Update. Nucleic Acids Res. 2020, 48, D783–D788. [CrossRef]

22. Yuliwulandari, R.; Kashiwase, K.; Nakajima, H.; Uddin, J.; Susmiarsih, T.P.; Sofro, A.S.M.; Tokunaga, K. Polymorphisms of HLA Genes in Western Javanese (Indonesia): Close Affinities to Southeast Asian Populations. Tissue Antigens 2019, 83, 3276–3278. [CrossRef]

23. World Population Review. Indonesia Population. Available online: https://worldpopulationreview.com/countries/indonesia-population (accessed on 1 October 2021).

24. Vilar, S.; Mahajan, S.; Overton, J.A.; Dhanda, S.K.; Martini, S.; Cantrell, J.R.; Wheeler, D.K.; Sette, A.; Peters, B. The Immune Epitope Database (IEDB); 2018 Update. Nucleic Acids Res. 2019, 47, D339–D343. [CrossRef] [PubMed]

25. Nelder, A.; Bishl, T.; Heitmann, J.; Maringer, Y.; Salih, H.; Roerden, M.; Lübke, M.; Bauer, J.; Rieth, J.; Wacker, M.; et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 2021, 22, 74–85. [CrossRef] [PubMed]
52. Yan, Y.; Zhang, D.; Zhou, P.; Li, B.; Huang, S.-Y. HDOCK: A Web Server for Protein–Protein and Protein–DNA/RNA Docking Based on a Hybrid Strategy. Nucleic Acids Res. 2017, 45, W369–W373. [CrossRef] [PubMed]

53. Kozakov, D.; Hall, D.R.; Xia, B.; Porter, K.A.; Padelocity, D.; Yueh, C.; Beglov, D.; Vajda, S. The ClusPro Web Server for Protein–Protein Docking. Nat. Protoc. 2012, 17, 255–278. [CrossRef]

54. Laskowski, R.A. PDBsum New Things. Nucleic Acids Res. 2009, 37, D355–D359. [CrossRef]

55. Blaszczyk, M.; Ciemny, M.P.; Kolinski, A.; Kurcinski, M.; Kmiecik, S. Protein–Peptide Docking Using CABS-Dock and Contact Information. Brief. Bioinform. 2019, 20, 2299–2305. [CrossRef] [PubMed]

56. Kurcinski, M.; Blaszczyk, M.; Ciemny, M.P.; Kolinski, A.; Kmiecik, S. A Protocol for CABS-Dock Protein–Peptide Docking Driven by Side-Chain Contact Information. Biomedical Eng. Online 2017, 16, 73–82. [CrossRef] [PubMed]

57. Blaszczyk, M.; Kurcinski, M.; Kouza, M.; Wieteska, L.; Debinski, A.; Kolinski, A.; Kmiecik, S. Modeling of Protein–Peptide Interactions Using the CABS-Dock Web Server for Binding Site Search and Flexible Docking. Methods 2016, 93, 72–83. [CrossRef] [PubMed]

58. Mullick, B.; Magar, R.; Jhunjhunwala, A.; Barati Farimani, A. Understanding Mutation Hotspots for the SARS-CoV-2 Spike Protein Using Shannon Entropy and K-Means Clustering. Comput. Biol. Med. 2021, 138, 104915. [CrossRef]

59. Thomas, S. Mapping the Nonstructural Transmembrane Proteins of Severe Acute Respiratory Syndrome Coronavirus 2. J. Comput. Biol. 2021, 28, 909–921. [CrossRef] [PubMed]

60. Santerre, M.; Arjona, S.P.; Allen, C.N.; Shcherbik, N.; Sawaya, B.E. Why Do SARS-CoV-2 NSPs Rush to the ER? Cell 2021, 185, 2013–2022. [CrossRef] [PubMed]

61. Gorkhali, R.; Koirala, P.; Rijal, S.; Mainali, A.; Baral, A.; Bhattarai, H.K. Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins. Bioinform. Biol. Insights 2021, 15, 11799322211025876. [CrossRef] [PubMed]

62. Stern, A.; Fleishon, S.; Kustin, T.; Dotan, E.; Mandelboim, O.; Erster, O.; Mendelson, E.; Mor, O.; Zuckerman, N.S.; Bucris, D.; et al. The Unique Evolutionary Dynamics in the SARS-CoV-2 Delta Variant-2 Sequencing. medRxiv 2021. [CrossRef]

63. Buckley, P.R.; Lee, C.H.; Pereira Pinho, M.; Ottakandathil Babu, R.; Woo, J.; Antanaviciute, A.; Simmons, A.; Ogg, G. HLA-Dependent Variation in the SARS-CoV-2 Delta Variant-2 Sequencing. bioRxiv 2021. [CrossRef]

64. Zhang, H.; Deng, S.; Ren, L.; Zheng, P.; Hu, X.; Jin, T.; Tan, X. Profiling CD8+ T Cell Epitopes of COVID-19 Convalescents Reveals Reduced Cellular Immune Responses to SARS-CoV-2 Variants. Cell Rep. 2021, 36, 109708. [CrossRef]

65. Mateus, J.; Grifoni, A.; Tarke, A.; Sidney, J.; Ramirez, S.I.; Dan, J.M.; Burger, Z.C.; Rawlings, S.A.; Smith, D.M.; Phillips, E.; et al. Selective and Cross- Reactive SARS-CoV-2 CD8+ T Cell Cross-Reactivity with Human Coronavirus. Science 2020, 370, 89–94. [CrossRef] [PubMed]

66. Grifoni, A.; Weiskopf, D.; Ramirez, S.I.; Mateus, J.; Dan, J.M.; Moderbacher, C.R.; Rawlings, S.A.; Sutherland, A.; Premkumar, L.; Jadi, R.S.; et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Uninfected Individuals. Cell 2020, 181, 1489–1501. [CrossRef] [PubMed]

67. Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Wendisch, D.; Erster, O.; Mendelson, E.; Mor, O.; Zuckerman, N.S.; Bucris, D.; et al. The Unique Evolutionary Dynamics of the SARS-CoV-2 Delta Variant-2 Sequencing. medRxiv 2021. [CrossRef]

68. le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.Y.L.; Hafezi, M.; Chia, A.; Chng, M.H.Y.; Lin, M.; Tan, N.; Linster, M.; et al. SARS-CoV-2-Specific T Cell Immunity in Cases of COVID-19 and SARS, and Uninfected Controls. Nature 2020, 584, 457–462. [CrossRef]

69. Saini, S.K.; Hersby, D.S.; Tamhane, T.; Povlsen, H.R.; Amaya Hernandez, S.P.; Nielsen, M.; Gang, A.O.; Hadrup, S.R. SARS-CoV-2 Genome-Wide T Cell Epitope Mapping Reveals Immunodominance and Substantial CD8+ T Cell Activation in COVID-19 Patients. Sci. Immunol. 2021, 6, eabj7550. [CrossRef] [PubMed]

70. Karami Fath, M.; Jahangiri, A.; Ganji, M.; Sefid, F.; Payandeh, Z.; Hashemi, Z.S.; Pourzardosht, N.; Hessami, A.; Mard-Soltani, M.; Zakeri, A.; et al. SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage. Front. Immunol. 2021, 12, 705772. [CrossRef] [PubMed]

71. Balz, K.; Kaushik, A.; Chen, M.; Cemic, F.; Heger, V.; Renz, H.; Nadeau, K.; Skevaki, C. Homologies between SARS-CoV-2 and Allergen Proteins May Direct T Cell-Mediated Heterologous Immune Responses. Sci. Rep. 2021, 11, 4792–4798. [CrossRef] [PubMed]

72. Hassan, M.M.; Sharmin, S.; Hong, J.; Lee, H.S.; Kim, H.J.; Hong, S.T. T Cell Epitopes of SARS-CoV-2 Spike Protein and Conserved Surface Protein of Plasmodium Malariae Share Sequence Homology. Open Life Sci. 2021, 16, 630–640. [CrossRef] [PubMed]

73. Haddad-Boubaker, S.; Othman, H.; Touati, R.; Ayouni, K.; Lakhal, M.; ben Mustapha, I.; Ghedira, K.; Kharrat, M.; Triki, H. In Silico Comparative Study of SARS-CoV-2 Proteins and Antigenic Proteins in BCG, OPV, MMR and Other Vaccines: Evidence of a Possible Putative Protective Effect. BMC Bioinform. 2021, 22, 163–176. [CrossRef]

74. Snyder, T.M.; Gittelman, R.M.; Klinger, M.; May, D.H.; Osborne, E.J.; Taniguchi, R.; Zahid, H.J.; Kaplan, I.M.; Dines, J.N.; Noakes, M.T.; et al. Magnitude and Dynamics of the T Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. medRxiv 2020. [CrossRef]

75. Prachar, M.; Justesen, S.; Steen-Jensen, D.B.; Thorgrimsen, S.; Jurgen, E.; Winther, O.; Bagger, F.O. Identification and Validation of 174 COVID-19 Vaccine Candidate Epitopes Reveals Low Performance of Common Epitope Prediction Tools. Sci. Rep. 2020, 10, 20465. [CrossRef]

76. Ibarroondo, F.J.; Fulcher, J.A.; Goodman-Meza, D.; Elliott, J.; Hofmann, C.; Hausner, M.A.; Ferbas, K.G.; Tobin, N.H.; Aldrovandi, G.M.; Yang, O.O. Rapid Decay of Anti–SARS–CoV–2 Antibodies in Persons with Mild COVID-19. N. Engl. J. Med. 2020, 383, 1085–1087. [CrossRef]
99. Rakib, A.; Sami, S.A.; Islam, M.A.; Ahmed, S.; Faiz, F.B.; Khanam, B.H.; Marma, K.K.S.; Rahman, M.; Uddin, M.M.N.; Nainu, F.; et al. Epitope-Based Immunoinformatics Approach on Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus-2. *Molecules* 2020, 25, 5088. [CrossRef]

100. Chakraborty, C.; Sharma, A.R.; Bhattacharya, M.; Sharma, G.; Lee, S.-S. Immunoinformatics Approach for the Identification and Characterization of T Cell and B Cell Epitopes towards the Peptide-Based Vaccine against SARS-CoV-2. *Arch. Med. Res.* 2021, 52, 362–370. [CrossRef]

101. Bhattacharya, M.; Sharma, A.R.; Mallick, B.; Sharma, G.; Lee, S.-S.; Chakraborty, C. Immunoinformatics Approach to Understand Molecular Interaction between Multi-Epitopic Regions of SARS-CoV-2 Spike-Protein with TLR4/MD-2 Complex. *Infect. Genet. Evol.* 2020, 85, 104587. [CrossRef]

102. Jakhar, R.; Gakhar, S.K. An Immunoinformatics Study to Predict Epitopes in the Envelope Protein of SARS-CoV-2. *Can. J. Infect. Dis. Med. Microbiol.* 2020, 2020, 7079356. [CrossRef]

103. Qiao, L.; Chen, M.; Li, S.; Hu, J.; Gong, C.; Zhang, Z.; Cao, X. A Peptide-Based Subunit Candidate Vaccine against SARS-CoV-2 Delivered by Biodegradable Mesoporous Silica Nanoparticles Induced High Humoral and Cellular Immunity in Mice. *Biomater. Sci.* 2021, 9, 7287–7296. [CrossRef]

104. Rahman, N.; Ali, F.; Basharat, Z.; Shehroz, M.; Khan, M.K.; Jeandet, P.; Nepovimova, E.; Kuca, K.; Khan, H. Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach. *Vaccines* 2020, 8, 423. [CrossRef] [PubMed]

105. Oladipo, E.K.; Ajayi, A.F.; Onile, O.S.; Ariyo, O.E.; Jimah, E.M.; Ezediuno, L.O.; Adebayo, O.I.; Adebayo, E.T.; Odeyemi, A.N.; Oyeleke, M.O.; et al. Designing a Conserved Peptide-Based Subunit Vaccine against SARS-CoV-2 Using Immunoinformatics Approach. *Silico Pharmacol.* 2021, 9, 8–28. [CrossRef]

106. Waqas, M.; Haider, A.; Rehman, A.; Qasim, M.; Umar, A.; Sufyan, M.; Akram, H.N.; Mir, A.; Razzaq, R.; Rasool, D.; et al. Immunoinformatics and Molecular Docking Studies Predicted Potential Multi-Epitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening. *BioMed Res. Int.* 2021, 2021, 1596834. [CrossRef]

107. Al Saba, A.; Adiba, M.; Saha, P.; Hosen, M.I.; Chakraborty, S.; Nabi, A.H.M.N. An In-Depth in Silico and Immunoinformatics Approach for Designing a Potential Multi-Epitope Construct for the Effective Development of Vaccine to Combat against SARS-CoV-2 Encompassing Variants of Concern and Interest. *Comput. Biol. Med.* 2021, 136, 104703. [CrossRef] [PubMed]

108. Crooke, S.N.; Ovsyannikova, I.G.; Kennedy, R.B.; Poland, G.A. Immunoinformatic Identification of B Cell and T Cell Epitopes in the SARS-CoV-2 Proteome. *Sci. Rep.* 2020, 10, 14179. [CrossRef] [PubMed]

109. Gangaev, A.; Ketelaars, S.L.C.; Patiwaal, S.; Dopler, A.; Hoevakker, K.; de Biasi, S.; Gibellini, L.; Mussini, C.; Gualdali, G.; Girardis, M.; et al. Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. *Nat. Commun.* 2021, 12, 2593–2606. [CrossRef] [PubMed]

110. Ferretti, A.P.; Kula, T.; Wang, Y.; Nguyen, D.M.V.; Weinheimer, A.; Dunlap, G.S.; Xu, Q.; Nabili, N.; Perullo, C.R.; Cristofaro, A.W.; et al. Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 That Largely Reside Outside the Spike Protein. *Immunity* 2020, 53, 1095–1107. [CrossRef] [PubMed]

111. Sohail, M.S.; Ahmed, S.F.; Quadeer, A.A.; McKay, M.R. In Silico T Cell Epitope Identification for SARS-CoV-2: Progress and Perspectives. *Adv. Drug Deliv. Rev.* 2021, 171, 29–47. [CrossRef] [PubMed]

112. Tan, A.T.; Sodsai, P.; Chia, A.; Moreau, E.; Chng, M.H.Y.; Tham, C.Y.L.; Ho, Z.Z.; Banu, N.; Hirankarn, N.; Bertoletti, A. Immunoprevalence and Immunodominance of HLA-Cw*0801-Restricted T Cell Response Targeting the Hepatitis B Virus Envelope Transmembrane Region. *J. Virol.* 2014, 88, 1332–1341. [CrossRef] [PubMed]